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Since the discovery of the family of hypocretin peptides in 1998, considerable 
evidence has accumulated showing that hypocretins promote wakefulness.  However, few 
studies have analyzed the interactions between hypocretins and other sleep-wake 
regulating neurotransmitters/neuromodulators.  The pontine reticular nucleus, oral part 
(PnO) is one brain region important for sleep-wake regulation where the interactions 
between hypocretin-1, γ-aminobutyric acid (GABA), and acetylcholine (ACh) have been 
investigated (Bernard et al., 2003; Watson et al., 2008b).  Whether these neurochemical 
interactions mediate the wakefulness promoting effects of hypocretin remains unclear.  
The main goal of my thesis research was to determine whether the increase in 
wakefulness caused by administering hypocretin-1 into the PnO is mediated by an 
interaction between hypocretinergic and GABAergic neurotransmission.       
The first section of this chapter provides an overview of the hypocretin system, 
including discovery of the peptides, structure-function analyses, signal transduction 
pathways, expression and distribution, and role in regulating sleep and wakefulness.  The 
second section discusses the role of the PnO in regulating the sleep-wake cycle and the 
principle sleep-wake regulating neurotransmitters in the PnO.  The third portion 
concludes with the overall thesis research question and the specific aims. 
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 THE HYPOCRETIN/OREXIN SYSTEM 
 
Discovery of the Hypocretin/Orexin System 
In 1998, two independent research groups simultaneously reported the discovery 
of hypocretins/orexins.  One of the groups characterized an mRNA sequence termed 
clone 35 that was initially isolated from rat hypothalamic extracts in 1996 (Gautvik et al., 
1996).  Further sequence analysis revealed that clone 35 encoded a precursor protein that 
localized in discrete nuclei within the posterior hypothalamus (de Lecea et al., 1998).  
Due to the hypothalamic origin and the phylogenic relation to the incretin family of 
peptides, clone 35 was named preprohypocretin (Figure 1.1A).  Proteolytic cleavage of 
preprohypocretin produces two neuropeptides amidated on the carboxyl terminus 
(hypocretin-1/orexin A and hypocretin-2/orexin B) (Figure 1.1B).  The authors concluded 
that hypocretins are a novel family of neuropeptides that might function to modulate 
feeding behavior.  
The other research group screened for fractions of brain extract that exhibited 
guanine nucleotide-binding protein (G protein)-coupled agonist activity with the goal of 
identifying ligands for orphan G protein-coupled receptors (GPCR) (Sakurai et al., 1998).  
Two hypothalamic peptides elicited an increase in calcium levels in cells stably 
expressing the orphan GPCR known as HFGAN72.  One hypothalamic peptide ligand 
was named orexin A (hypocretin-1) and the other orexin B (hypocretin-2).  HFGAN72 
was renamed orexin receptor-1 (hypocretin receptor-1).  Orexin receptor-2 (hypocretin 
receptor-2) was identified by searching for sequences that closely matched orexin 
receptor-1.  After finding that intracerebroventricular (i.c.v.) injection of orexin A in rat 
caused an increase in feeding behavior the peptides were named orexins, which is derived 
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from the Greek word for appetite (orexis).  Hypocretins and orexins are synonymous and 




















Figure 1.1.  Hypocretin Gene and Peptide Structure.  (A) Schematic representation of 
human preprohypocretin showing key structural features.  Preprohypocretin is cleaved by 
prohormone convertases at dibasic residues GKR and GKK to produce hypocretin-1 and 
hypocretin-2.  (B) Hypocretin-1 is a 33 amino acid peptide with two disulfide bonds.  
Hypocretin-2 is a 29 amino acid linear peptide.  Residues underlined are conserved 
between the two peptides.  The C-terminal of both peptides is amidated.  (Source: 
modified from Taheri et al., 2002).  (C) Alignment of hypocretin (orexin) sequences 
across species.  Highlighted residues are conserved across species (Source: modified 




Evidence linking hypocretins to the sleep disorder narcolepsy 
Although it was hypothesized that hypocretins were mainly involved in feeding 
behavior, it was soon discovered that hypocretin signaling is also important for 
maintaining wakefulness.  The importance of hypocretin signaling in maintaining 
wakefulness became evident in 1999 when 1) a mutation in hypocretin receptor-2 (hcrt-
r2) caused narcolepsy in dogs (Lin et al., 1999), and 2) preprohypocretin knockout mice 
exhibited symptoms of narcolepsy (Chemelli et al., 1999).  Another study showed that 
genetic ablation of the preprohypocretin gene in rats also caused a narcoleptic phenotype 
(Beuckmann et al., 2004).  Narcolepsy is a sleep disorder characterized by excessive 
daytime sleepiness, disrupted nighttime sleep, hypnogogic hallucinations, sudden onset of 
REM sleep, and cataplexy.  The incidence of narcolepsy is 1 in 2000 persons (Mignot, 
1998), which is close to the order of incidence for Parkinson’s Disease (1:1000) and more 
than Huntington’s Disease (1:5000) (van den Pol, 2000).  
Several studies confirmed the contribution of hypocretin deficiency to the 
pathophysiology of human narcolepsy.  Post-mortem brains of narcoleptics lack 
hypocretinergic neurons (Peyron et al., 2000; Thannickal et al., 2000) and the level of 
hypocretin-1 in the cerebrospinal fluid (CSF) of narcoleptic patients is undetectable 
(Nishino et al., 2000; Mignot et al., 2002).  Measurement of hypocretin-2 in CSF is 
difficult (Ripley et al., 2001) and hypocretin-2 appears to be less stable than hypocretin-1 
(Kastin and Akerstrom, 1999).  Lesion of hypocretin-2-expressing neurons in the lateral 
hypothalamus of rat causes an increase in sleep and a decrease in wakefulness 
(Gerashchenko et al., 2001), and the relative loss of hypocretin-2-expressing neurons 
correlates with the amount of sleep observed (Gerashchenko et al., 2003).  The cause of 
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hypocretin deficiency in narcoleptic patients in not known, but a close association 
between narcolepsy and the expression of human leukocyte antigen-DQB1*0602 
(Mignot, 1997) suggests an autoimmune basis for narcolepsy.  Consistent with the 
autoimmune hypothesis, a recent study showed that narcolepsy is also closely associated 
with another immune related risk factor, a variant T-cell receptor alpha (Hallmayer et al., 
2009).   
In order to understand the differential roles of hypocretin receptor-1 (hcrt-r1) and 
hcrt-r2 in regulating sleep and wakefulness, hcrt-r1, hcrt-r2, and double receptor 
knockout mice were developed and analyzed for changes in the sleep-wake cycle (Willie 
et al., 2001; Willie et al., 2003).  Hcrt-r2 knockout mice share the same sleep-related 
phenotypes as the preprohypocretin knockout mice (Willie et al., 2001; Willie et al., 
2003).  Preprohypocretin knockout mice exhibit symptoms of narcolepsy, including 
episodes of cataplexy, but have normal amounts of wakefulness and sleep (Chemelli et 
al., 1999).  Hcrt-r1 knockout mice are asymptomatic (reviewed in Willie et al., 2003), 
suggesting that hcrt-r2 is more important for maintaining wakefulness.  However, hcrt-
r1/hcrt-r2 double knockout mice exhibit more frequent wake to REM sleep transitions 
with cataplexy than the hcrt-r2 knockout mice, demonstrating that both hypocretin 
receptor subtypes are required for the maintenance of wakefulness (Willie et al., 2001; 
Willie et al., 2003).  Hypocretin receptor mutations are rare in humans, but there are 
patients with single nucleotide polymorphisms in hcrt-r2 (Thompson et al., 2004) that 
have excessive daytime sleepiness.  With the advent of hypocretin receptor antagonists, 
further studies are exploring the relative importance of hypocretin receptor subtypes in 
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regulating wakefulness.  Hypocretin receptor antagonist studies will be discussed in more 
detail later in this introduction. 
Hypocretin gene and peptide structure 
Hypocretin-1 is a 33 amino acid peptide of 3562 Daltons that contains two 
intramolecular disulfide bonds, and hypocretin-2 is a linear 28 amino acid peptide of 
2937 Daltons (Figure 1.1B).  Hypocretin-1 and hypocretin-2 share 46% sequence 
homology and are highly conserved across species, including Xenopus laevis (Figure 
1.1C).  Human, rat, dog, and mouse hypocretin-1 are identical whereas rodent and human 
hypocretin-2 differ by two amino acids.  Secretin, a member of the incretin family, shares 
a tandem of 7 amino acids with hypocretin-2.  Although the sequence homology between 
secretin and hypocretins is relatively weak, it appears that hypocretins emerged from 
secretin by genetic rearrangements (Alvarez and Sutcliffe, 2002).  Human hypocretin-2 
structure was determined using nuclear magnetic resonance spectroscopy and it is 
structurally similar to neuropeptide Y.  Hypocretin-2 consists of a random coil at the 
amino-terminal followed by two alpha helices that are connected by a short flexible 
linker (Lee et al., 1999).  
Hypocretin receptor pharmacology and signaling pathways 
Hcrt-r2 shares 64 % sequence homology with hcrt-r1 (Sakurai et al., 1998).  Both 
receptor genes are highly conserved between human and rat (greater than 94 %).  The N-
terminus extracellular domain of GPCRs is important for agonist recognition and binding 
and is highly conserved between hcrt-r1 and hcrt-r2.  The intracellular loop III and the C-
terminus of GPRCR interact with G proteins and there is weak amino acid sequence 
identity in these regions of hcrt-r1 and hcrt-r2 (Sakurai et al., 1998).  Radioligand binding 
and calcium mobilization assays determined that hcrt-r2 binds hypocretin-1 and 
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hypocretin-2 with similar affinities whereas hcrt-r1 is highly selective for hypocretin-1 
(Sakurai et al., 1998).  Hcrt-r2 is a nonselective receptor for both hcrt-1 and hcrt-2 
whereas hcrt-r1 is selective for hypocretin-1.   
Hypocretin receptors couple to multiple G proteins and thus to multiple signal 
transduction pathways.  Activation of different types of G proteins (e.g., Gs, Gq, Gi) 
triggers different signaling cascades and effector proteins.  For example, activation of Gs 
proteins elevates adenylyl cyclase activity to activate protein kinase A (PKA) which 
results in an increased calcium mobilization and neuronal excitability.  Activation of Gq 
increases calcium conductance and neuronal excitability by activating phospholipases.  A 
number of studies investigated the contribution of different G protein types to either hcrt-
r1 or hcrt-r2-mediated changes in membrane conductance, calcium influx, or downstream 
effectors of G protein receptor activation.  Most of the studies used cell lines over 
expressing either hcrt-r1 or hcrt-r2 (Randeva et al., 2001; Hoang et al., 2003; Zhu et al., 
2003; Holmqvist et al., 2005; Johansson et al., 2008).  Initially, it appeared that hcrt-r1 
coupled to Gq proteins to stimulate phospholipase C and that hcrt-r2 coupled to either Gq 
or Gi proteins (Zhu et al., 2003). However, hypocretin receptor signaling proved very 
complex.  In vitro studies demonstrated that hcrt-r1 couples to Gs, Gq, or Gi proteins, 
depending on the tissue type and response elicited by hypocretin-1 (Bernard et al., 2003; 
Hoang et al., 2003; Holmqvist et al., 2005; Bernard et al., 2006).  Furthermore, hcrt-r1 
differentially coupled to Gs or Gq, depending on the concentration of hypocretin-1 
administered (Holmqvist et al., 2005).  What this means physiologically is not known.  
Depending on the region within the rat brainstem, G protein activation showed different 
pharmacological profiles in response to hypocretin-1 (Bernard et al., 2003, 2006).  
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Similar to hcrt-r1, hcrt-r2 couples either to Gs, Gq or Gi proteins depending on the tissue 
type and response elicited by hypocretin-1 (Randeva et al., 2001; Tang et al., 2008).  
How hcrt-r2 or hcrt-r1 couple to different G proteins is not well understood, but it 
is proposed that tissue type, physiological demands (e.g., food deprivation), and receptor 
density may influence differential coupling (Karteris and Randeva, 2003).  In addition to 
binding different G proteins, studies have alluded to hypocretin receptor dimerization 
(Ammoun et al., 2003; Hilairet et al., 2003), further complicating hypocretin receptor 
signaling.   
Hypocretin structure activity analyses 
Few studies have evaluated the molecular determinants for hcrt-r1 and hcrt-r2 
binding.  As mentioned previously, hypocretin-1 is selective for hcrt-r1 whereas both 
hypocretin-1 and hypocretin-2 can activate hcrt-r2.  The carboxyl-termini of hypocretin-1 
and hypocretin-2 share approximately 73% sequence homology and hypocretin-2 can be 
thought of as an N-terminally truncated variant of hypocretin-1.  Indeed, truncating the 
N-terminus of hypocretin-1 (residues 14 or 15-33 amino acids remaining) reduced its 
potency and affinity at hcrt-r1 (Darker et al., 2001).  The C-termini of hypocretin-1 and 
hypocretin-2 are highly conserved and studies show that the C-terminus is important for 
hypocretin receptor binding and activation (Darker et al., 2001; Ammoun et al., 2003; 
Lang et al., 2004).  Whether the disulfide bonds within hypocretin-1 are important for 
biological activity is still under debate (Okumura et al., 2001; Lang et al., 2004).  
Currently, there are modified hypocretin-2 synthetic peptides that are more selective for 
hcrt-r2 than unmodified hypocretin-2 and hypocretin-1 (Asahi et al., 2003; Lang et al., 
2004; Lang et al., 2006).  Recently, a hypocretin-1 synthetic peptide was created and is 
more selective for hcrt-r1 than non-modified hypocretin-1 (Lang et al., 2004).  
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Hypocretin system neuroanatomy 
Hypocretinergic neurons reside in the perifornical, lateral, and posterior 
hypothalamus in rat (Peyron et al., 1998; Nambu et al., 1999), and the lateral 
hypothalamus in human (Elias et al., 1998).  There are approximately 7000 
hypocretinergic neurons in rat lateral hypothalamus (Peyron et al., 1998; Modirrousta et 
al., 2005) and roughly 20-70,000 hypocretinergic neurons in human lateral hypothalamus 
(Peyron et al., 1998; Thannickal et al., 2000).  The number of hypocretinergic neurons in 
human brain was estimated using either in situ hybridization (Peyron et al., 1998) or 
immunohistochemistry (Thannickal et al., 2000). 
Hypocretin-containing neurons have widespread projections to a number of brain 
regions and only the cerebellum lacks projections from hypocretinergic neurons (Peyron 
et al., 1998; Nambu et al., 1999) (Figure 1.2).  Hypocretinergic neurons abundantly 
innervate noradrenergic cells of the locus coeruleus neurons, serotonergic cells of the 
dorsal raphe, histaminergic cells of the tuberomammillary nucleus, and cholinergic cells 
of the laterodorsal tegmental/pedunculopontine tegmental nucleus (LDT/PPT) and basal 
forebrain (Peyron et al., 1998; Nambu et al., 1999).  Hypocretins were initially implicated 
in regulating sleep and wakefulness because hypocretin-containing neurons project to 
brain areas important for promoting wakefulness, such as the locus coeruleus, 
tuberomammillary nucleus, and LDT/PPT.  In addition to a role in regulating sleep and 
wakefulness, there is considerable evidence that hypocretins are involved in feeding, 
temperature regulation, endocrine secretion, and addiction (reviewed in Sharf et al.; 
Sakurai, 2007; Tsujino and Sakurai, 2009).  The hypothalamus, where hypocretinergic 
neurons are located, is a homeostatic center of control and receives reciprocal projections 
from multiple brain regions.  Hypocretinergic neurons are subject to tight regulation and 
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Table 1.1 summarizes the neuromodulators and neurotransmitters that influence 
hypocretinergic activity in the hypothalamus (reviewed in Willie et al., 2001; Tsujino and 
Sakurai, 2009).     
The distribution of hcrt-r1 and hcrt-r2 mRNA closely matches brain regions 
innervated by hypocretinergic neurons (Trivedi et al., 1998; Marcus et al., 2001).  Hcrt-r1 
and hcrt-r2 mRNA are distributed in some of the same brain regions, such as the ventral 
tegmental area and dorsal raphe, but hcrt-r1 and hcrt-r2 mRNA are also differentially 
distributed in the brain (Trivedi et al., 1998; Greco and Shiromani, 2001; Marcus et al., 
2001).  Hcrt-r1 mRNA and protein are abundantly expressed in the locus coeruleus and 
are also found in the anterior and ventro-medial hypothalamic areas, paraventricular 
thalamic nucleus, pontine reticular formation, hippocampus, LDT/PPT, and the bed 
nucleus of the stria terminalis (Trivedi et al., 1998; Greco and Shiromani, 2001; Marcus 
et al., 2001). mRNA for hcrt-r2 is highly expressed in the tuberomammillary nucleus and 
in other hypothalamic nuclei (Trivedi et al., 1998; Marcus et al., 2001) with lower levels 
of hcrt-r2 protein present in the dorsal tegmental nucleus and caudal pontine reticular 
formation (Greco and Shiromani, 2001).  The distinct pattern of hypocretin receptor 
subtype expression suggests different physiological roles for hcrt-r1 and hcrt-r2 in 






Figure 1.2.  Hypocretinergic pathways in the rat brain.  Hypocretin neurons originate in 
the lateral hypothalamus (shown as green circles) and project to a wide range of brain 






Factors that influence the activity of hypocretin neurons 
       Receptor Involved 
Excitation 
Glutamate       AMPAR, NMDAR mGluRs 
Acetylcholine (muscarinic) (27%)    M3 
Ghrelin       GHSR 
Cholecystokinin      CCKA 
Neurotensin       NTSR2a 
Vasopressin       V1a 
Oxytocin       V1a 
Glucagon-like peptide 1     N.D. 
CRF        CRFR1 
Thyrotropin-releasing hormone    TRH1 
ATP        P2X 
H+, CO2       N.D. 
Inhibition 
Glucose       Unknown 
GABA       GABAA, GABAB 
Serotonin       5HT1A 
Noradrenaline       α2 
Dopamine        α2 
Acetylcholine (muscarinic) (6%)    N.D. 
NPY        Y1 
Enkephalin         μ Opioid receptor 
Nociceptin       NOPR 
Leptin        OBR 
Adenosine       A1 
 
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; mGluR, 
metabotropic glutamate receptor; M3, muscarinic acetylcholine receptor M3; GHSR, 
ghrelin secretagogue receptor; CCKA, type A cholecystokinin receptor; NTSR2, 
neurotensin receptor 2; N.D., not determined; CRFR1, CRF-releasing factor 1; TRH1, 
thyrotropin-releasing hormone receptor 1; NOPR, nociceptin/orphanin FQ receptor; 
OBR, astrocyte leptin receptor 
a N. Furutani, T. Abe, M. Hondo, T. Matsuki, N. Tsujino, K. Ichiki, M. Mieda, I. 
Matsuzaki, H. Takahishi, A. Yamanaka, and T. Sakurai, unpublished observations.  




Involvement of the hypocretin/orexin system in sleep and wakefulness 
Hypocretinergic neurons innervate all major sleep-wake regulating brain areas 
(Peyron et al., 1998; Nambu et al., 1999; Taheri et al., 1999).  The locus coeruleus 
receives the densest hypocretinergic projections and application of hypocretin-1 has a 
direct excitatory effect on locus coeruleus neurons (Hagan et al., 1999; Horvath et al., 
1999; Bourgin et al., 2000).  Neurons in the locus coeruleus fire maximally during 
wakefulness compared to NREM sleep and REM sleep (Aston-Jones and Bloom, 1981; 
Berridge and Foote, 1996).  The first functional study demonstrating that hypocretins are 
involved in regulating sleep and wakefulness showed that i.c.v. administration of 
hypocretin-1 causes an increase in wakefulness and a decrease sleep (Hagan et al., 1999).  
The increase in wakefulness caused by i.c.v. administration of hypocretin-1 was due to an 
increase in the duration of wakefulness episodes (Piper et al., 2000).  Monoaminergic 
neurons located in the tuberomammillary nucleus (Bayer et al., 2001; Eriksson et al., 
2001; Yamanaka et al., 2002) and dorsal raphe (Brown et al., 2001; Brown et al., 2002; 
van den Pol et al., 2002) are also excited by hypocretin-1.  Cholinergic neurons in the 
basal forebrain (Eggermann et al., 2001) and LDT/PPT (Burlet et al., 2002; Takahashi et 
al., 2002; Kim et al., 2009) depolarize in response to hypocretin-1.  Hypocretinergic 
neurons in the lateral hypothalamus discharge at their fastest rates during active 
wakefulness (Takahashi et al., 2002; Lee et al., 2005; Mileykovskiy et al., 2005) and 
exhibit bursts of discharge during the phasic muscle twitches characteristic of REM sleep 
(Takahashi et al., 2002; Mileykovskiy et al., 2005).  Higher CSF levels of hypocretin-1 
were observed during active waking with movement (Kiyashchenko et al., 2002) and 
i.c.v. administration of hypocretin-1 increased motor activity in rats (Hagan et al., 1999; 
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Piper et al., 2000), suggesting that hypocretin-1 is involved in motor activity.  Whether 
the primary function of hypocretin is to enhance motor activity is still debated. 
Hypocretin-1 levels in the lateral hypothalamus gradually increase throughout the active 
period and decrease during sleep (Yoshida et al., 2001; Kiyashchenko et al., 2002), 
further supporting the interpretation that hypocretin-1 promotes wakefulness.  Moreover, 
hypocretin-1 levels in the CSF of dog increased after 24 hours of sleep deprivation (Wu 
et al., 2002), indicating that the increased hypocretin-1 levels might function to oppose 
sleep pressure.  The activity of hypocretinergic neurons increased after total sleep 
deprivation (Modirrousta et al., 2005) and after REM sleep deprivation (Verret et al., 
2003).  Although the activity of hypocretinergic neurons increased after sleep deprivation 
(Verret et al., 2003; Modirrousta et al., 2005), stimulation of hypocretinergic neurons was 
not sufficient to keep sleep-deprived subjects awake (Carter et al., 2009).  However, 
stimulation of hypocretinergic neurons during NREM sleep or REM sleep increased the 
probability of sleep to wake transitions (Adamantidis et al., 2007). Aged rats and mice 
display fragmentation of wakefulness (Mendelson and Bergmann, 1999) and have 
decreased hypocretin receptor expression (Terao et al., 2002).  Taken together, these 
studies suggest a role for hypocretin in maintaining wakefulness.  
Hypocretin receptor antagonists 
 Initially, pharmaceutical interest in the hypocretin system was focused on finding 
a way to administer hypocretin for the treatment of narcolepsy (reviewed in Fujiki and 
Nishino, 2005).  However, there is a growing interest in treating insomnia with 
hypocretin receptor antagonists (reviewed in Nishino, 2007).  In addition to the clinical 
applications of hypocretin receptor antagonists, subtype-specific antagonists of 
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hypocretin receptors will be useful to differentiate the physiological roles of hypocretin 
receptors. 
 The first hypocretin receptor antagonist, SB-334867 (N-(2-Methyl-6-
benzoxazolyl)-N″-1,5-naphthyridin-4-yl urea), was developed by SmithKline Beecham 
Pharmaceuticals (Smart et al., 2001).  Calcium mobilization studies showed that SB-
334867 has an affinity of 40 nM at hcrt-r1 and 2000 nM for hcrt-r2.  SB-334867 does not 
show any significant affinities over a panel of 50 GPCRs and ion channels (Smart et al., 
2001).  A number of studies have used SB-334867 in a variety of behavioral models 
(reviewed in Upton, 2005).  For example, SB-334867 blocks the decrease in resting 
duration induced by i.c.v. hypocretin-1 (Rodgers et al., 2001), increase in grooming 
behavior (Duxon et al., 2001), decrease in REM sleep (Smith et al., 2003), increase in 
thermogenesis (Kiwaki et al., 2004) as well as the increase in antinociception caused by 
administration of hypocretin-1 to the PnO (Watson et al., 2009).  Intraperitoneal injection 
of SB-334867 alone increased resting time in rats (Rodgers et al., 2001), increased sleep 
(Smith et al., 2003), and delayed emergence from isoflurane (Kelz et al., 2008) and 
sevoflurane (Kelz et al., 2008; Dong et al., 2009) anesthesia.  SB-408124 (1-(6,8-difluro-
methyl-quinoline-4-yl)-3-(4-dimethylamino-phenyl)-urea is another hypocretin receptor-
1 antagonist that has an affinity of 6 nM at hcrt-r1 and 2000 nM for hcrt-r2.  Few studies 
have used SB-408124 (reviewed in Upton, 2005).  One study showed that subcutaneous 
administration of SB-408124 in rat did not alter sleep-wake states (Dugovic et al., 2009).  
 In 2003, the first hcrt-r2 antagonist, N-Acyl 6-7-dimetyoxy-1,2,3,4-
tetrahydroisoquinoline was reported (Hirose et al., 2003).  This compound has not yet 




yl]urea) (McAtee et al., 2004), that has an affinity of 80 nM for hcrt-r2 and 6000 nM for 
hcrt-r1.  Only two studies have used JNJ-10397049 (Borgland et al., 2008; Dugovic et al., 
2009) and one of these studies (Dugovic et al., 2009) showed that subcutaneous 
administration in rat decreased wakefulness and increased sleep. 
 A relatively recent study demonstrated that oral administration of the dual 
hypocretin receptor antagonist almorexant in rat, human, and dog increased sleep 
(Brisbare-Roch et al., 2007).  The sleep-promoting effects were mainly due to blocking 
hcrt-r2 signaling, depending on the sleep parameter analyzed (Dugovic et al., 2009).  
Furthermore, the hcrt-r1 antagonist attenuated the increase in NREM sleep caused by the 
hcrt-r2 antagonist (Dugovic et al., 2009).  The mechanisms are not well understood, but 
hcrt-r1 and hcrt-r2 may differentially alter levels of arousal-promoting neurotransmitters.  
Hypocretin receptors bind different G proteins and potentially dimerize with other 
hypocretin receptors or other GPCRs.  Furthermore, different sleep-wake regulating brain 
regions express different densities and subtypes of hypocretin receptors, adding another 
level of complexity to the mechanisms by which hypocretins are wakefulness promoting.   
Hypocretins interacts with multiple neurotransmitters to modulate sleep and 
wakefulness 
Several studies have investigated the brain-region-specific effects of hypocretin-1 
and -2 in regulating the sleep-wake cycle.  Administration of hypocretin-1 into the locus 
coeruleus (Bourgin et al., 2000), preoptic area (Methippara et al., 2000), basal forebrain 
(Espana et al., 2001; Blanco-Centurion et al., 2006), and LDT (Xi et al., 2001) increased 
wakefulness and decreased sleep.  Although hypocretinergic neurons project to all the 
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major wakefulness promoting brain regions, modulation of sleep and wakefulness is 
dependent on the interplay and coordination of multiple neurotransmitters.   
Histamine is another wakefulness-promoting neurotransmitter that has been 
shown to interact with hypocretins.  For example, intraperitoneal injection of a histamine 
synthesis inhibitor blocked the increase in wakefulness caused by hypocretin-1 (Yasuko 
et al., 2010).  Histamine levels were significantly lower in the cortex, thalamus, and 
hippocampus of hcrt-r2 knockout narcoleptic dogs as compared to control dogs (Nishino 
et al., 2001). Furthermore, a recent report demonstrated that enhancement of 
histaminergic transmission reduced cataplexy and sleep in narcoleptic dogs (Guo et al., 
2009).  
Adenosine is a sleep-promoting modulator that has also been shown to interact 
with hypocretin.  Brain levels of adenosine normally increase after sleep deprivation, but 
lesioning hypocretinergic neurons prevented the increase in adenosine levels after sleep 
deprivation (Murillo-Rodriguez et al., 2008).  Adenosine A1 receptors are expressed on 
hypocretinergic neurons (Thakkar et al., 2002), and blockade of A1 receptors in the 
lateral hypothalamus inhibits the sleep-promoting effects of adenosine (Thakkar et al., 
2002; Alam et al., 2009).   
Glutamate is the major neurotransmitter in the brain and interacts with hypocretin 
in the hypothalamus.  Microdialysis delivery of hypocretin-1 into the substantia 
innominata increased glutamate levels (Fadel and Frederick-Duus, 2008).  Application of 
hypocretin-1 to the lateral hypothalamus stimulated glutamate release (Li et al., 2002).  
Microinjection of glutamate into the lateral hypothalamus increased wakefulness (Alam 
and Mallick, 2008) suggesting that hypocretin and glutamate interact to promote 
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wakefulness.  Antagonist blocking studies are needed to confirm that the interaction 
between hypocretin and glutamate modulates sleep and wakefulness. 
Several studies demonstrate that hypocretin modulates neuronal firing properties 
(reviewed in Nunez et al., 2009) and the release of other sleep-wake neurotransmitters in 
a number of brain regions (reviewed in Watson, 2010).  All of these neurochemical 
interactions in different brain regions are important in dictating the resulting behavioral 
state. 
 
OVERVIEW OF THE PONTINE RETICULAR NUCLEUS, ORAL PART  
 
The ascending reticular activating system  
 
 The concept of the ascending reticular formation (ARAS) was first described in 
1949 by Moruzzi and Magoun.  Until this time, it was thought that sensory stimulation 
was required for triggering and maintaining wakefulness, and that cessation of sensory 
stimulation resulted in sleep.  Moruzzi and Magoun found that stimulation of the 
brainstem reticular formation of anesthetized or sleeping cats resulted in 
electroencephalogram (EEG) signals that were identical to those of wakefulness (Moruzzi 
and Magoun, 1949).  Furthermore, if the brainstem reticular formation was destroyed 
then sensory stimulation no longer resulted in arousal (Lindsley et al., 1950).  Taken 
together, these seminal studies demonstrated that the reticular formation has the capacity 
to maintain wakefulness in the absence of sensory stimulation.  The ARAS connects the 
brainstem reticular formation, including the pontine nucleus, oral part (PnO), to areas in 
the thalamus, hypothalamus, and cortex.  The PnO contributes to the generation of 
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cortical arousal that is characteristic of wakefulness and rapid eye movement (REM) 
sleep (Lydic and Baghdoyan, 2005).  The focus of my studies was the PnO.  
The arousal-related activity of the PnO is regulated by the interplay of multiple 
neurotransmitter systems and brain regions.  The PnO receives cholinergic input from the 
LDT/PPT (Mitani et al., 1988; Shiromani et al., 1988), serotonergic input from the dorsal 
raphe, nucleus prosupralemniscus (B9 cell group) (Semba, 1993), ventral mesopontine 
tegmentum, and dorsal mesopontine tegmentum (Rodrigo-Angulo et al., 2000), 
noradrenergic input from the locus coeruleus and lateral tegmentum (Semba, 1993), 
histaminergic input from the tuberomammillary nucleus (Semba, 1993), and 
hypocretinergic input from the lateral hypothalamus (Peyron et al., 1998).  The PnO also 
receives GABAergic projections from the zona incerta (Border et al., 1986), 
caudal/dorsal hypothalamus (Rodrigo-Angulo et al., 2008), posterior hypothalamus (De 
La Roza et al., 2004), reticular thalamic nucleus (Reinoso-Suarez et al., 1994), and 
contralateral PnO (Liang and Marks, 2009).  Glutamate is a major signaling molecule in 
the PnO (Kaneko et al., 1989; Lai et al., 1999), and it has been suggested that one side of 
the PnO receives glutamatergic projections from the contralateral PnO (Lai et al., 1999). 
Cholinergic transmission in the PnO 
Multiple lines of evidence support a central role for ACh in cat, rat, and mouse 
PnO in generating REM sleep (Baghdoyan et al., 1984b; Baghdoyan et al., 1984a, 1987; 
Baghdoyan et al., 1989; Bourgin et al., 1995; Marks and Birabil, 1998; Coleman et al., 
2004; Douglas et al., 2005; Marks and Birabil, 2007).  ACh release in the pontine 
reticular formation is significantly higher during REM sleep than during wakefulness or 
NREM sleep (Kodama et al., 1990; Leonard and Lydic, 1995, 1997).  ACh acts on two 
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major classes of receptors, nicotinic and muscarinic.  There are five muscarinic receptor 
(mAChR) subtypes (M1, M2, M3, M4, and M5).  M1, M3, and M5 receptors are coupled 
to excitatory Gq proteins whereas M2 and M4 receptors are coupled to inhibitory G-
proteins.  Receptor audioradiography studies in vitro show that M2 receptors represent 
the major mAChR subtype in the pontine reticular formation (Baghdoyan et al., 1994; 
Baghdoyan, 1997).  Considerable evidence suggests that M2 receptors in the pontine 
reticular formation are critical for induction of REM sleep (Baghdoyan et al., 1994; 
Bourgin et al., 1995; Baghdoyan, 1997; Baghdoyan and Lydic, 1999).  Cholinergic 
enhancement of REM sleep is dependent on M2 receptor inhibition of adenylate cyclase 
and PKA activities (Capece and Lydic, 1997; Marks and Birabil, 2000).   
The PnO does not contain cholinergic neurons and receives cholinergic 
projections from the LDT/PPT (Mitani et al., 1988; Shiromani et al., 1988).  Stimulation 
of the LDT/PPT increases REM sleep (Thakkar et al., 1996) and ACh release in the 
pontine reticular formation (Lydic and Baghdoyan, 1993).  Although it is clear that ACh 
is important for generating REM sleep there are studies that show administration of high 
concentrations of cholinomimetics into the PnO increases wakefulness (Bourgin et al., 
1995; Marks and Birabil, 2001).  The mechanisms by which ACh in the pontine reticular 
formation increases wakefulness are unknown.  Application of the nonspecific 
cholinergic agonist carbachol either depolarizes or hyperpolarizes PnO neurons (Greene 
and Carpenter, 1985; Nuñez et al., 1998; Brown et al., 2006; Brown et al., 2008), 
suggesting that carbachol activates mAChRs located on either GABAergic or non-
GABAergic neurons.  A recent study demonstrated that carbachol either inhibits or 
excites GABAergic neurons in the PnO (Brown et al., 2008).  One possible explanation is 
 20
 
that GABAergic neurons in the PnO express either M2/M4 receptors or M1/M2/M5 
receptors.  Activation of M2/M4 receptors on GABAergic neurons in the PnO would 
result in depolarization whereas activation of M1/M2/M5 receptors on GABAergic 
neurons would result in hyperpolarization.  Whether the ACh-induced increase in 
wakefulness or REM sleep is related to the differential firing patterns caused by ACh is 
unknown.  These data suggest that ACh and GABA interact to modulate neuronal activity 
in the PnO, and thus sleep and wakefulness.  
GABAergic transmission in the PnO 
Studies using light (Mugnaini, 1985; Ford et al., 1995) and electron (Reinoso-
Suarez et al., 2001; De La Roza et al., 2004; de la Roza and Reinoso-Suarez, 2006) 
microscopy demonstrate that neurons in the PnO of cat are immunopositive for GABA.  
Furthermore, it is estimated that 30% of all synapses in cat PnO are GABAergic (de la 
Roza and Reinoso-Suarez, 2006).  Immunohistochemical studies indicate the presence of 
GABAergic interneurons in the pontine reticular formation of cat (Brodal et al., 1988; 
Aas, 1989; de la Roza and Reinoso-Suarez, 2009), primate (Brodal et al., 1988), and rat 
(Liang and Marks, 2009). 
 Systemically administered GABAmimetics are well known to elicit sleep or 
anesthesia.  Delivery of a GABAA receptor agonist directly into the posterior 
hypothalamus (Lin et al., 1989) increases wakefulness.  Increased wakefulness, however, 
is produced after administration of GABAergic drugs directly into the preoptic 
area/anterior hypothalamus (Lin et al., 1989).  Therefore, GABAmimetics have opposite 
effects on sleep and wakefulness depending upon their site of action in the brain. 
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GABAA receptor signaling in the PnO promotes wakefulness (Camacho-Arroyo 
et al., 1991; Xi et al., 1999) and suppresses REM sleep (Xi et al., 1999; Sanford et al., 
2003; Vazquez and Baghdoyan, 2004; Marks et al., 2008).  Increasing or decreasing 
endogenous GABA levels in the PnO causes an increase or decrease, respectively, in 
wakefulness (Watson et al., 2008b).  Furthermore, GABA levels in the PnO are lower 
during isoflurane anesthesia than during wakefulness (Vanini et al., 2008). 
 Intracellular recordings show that rat pontine neurons exhibit inhibitory 
postsynaptic potentials mediated by GABAA receptors (Nuñez et al., 1998).  Consistent 
with the finding that GABAergic neurons in the PnO express M2 receptors (Brischoux et 
al., 2008) are data showing that carbachol either inhibits or excites GABAergic neurons 
in the PnO (Brown et al., 2008).  Further support for the concept that GABA and ACh 
interact in the PnO is evidence demonstrating that GABAA receptors in the PnO inhibit 
ACh release (Vazquez and Baghdoyan, 2004).  A recent study demonstrated that the 
REM sleep enhancement caused by administration of the GABAA receptor antagonist, 
gabazine, to the PnO, is dependent on cholinergic transmission (Marks et al., 2008).  
Taken together, these data suggest that GABAA receptor signaling in the PnO alters states 
of sleep and wakefulness, in part, by modulating ACh release.  However, the PnO is 
composed of a heterogeneous population of neuronal types and it is likely that GABA 
interacts with other neurotransmitters to modulate states of sleep and wakefulness. 
Hypocretinergic transmission in the PnO 
The first study to investigate the effect of hypocretin in the PnO in modulating 
sleep and wakefulness was done in 2001.  Microinjection of hcrt-r2 antisense into the 
pontine reticular formation increased REM sleep, suggesting that hypocretins target the 
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pontine reticular formation to control REM sleep by activating hcrt-r2 (Thakkar et al., 
2001).  It was later shown that administration of hypocretin-1 into the PnO caused an 
increase in REM sleep (Xi et al., 2002).  However, further studies revealed that the effect 
of hypocretin-1 in the PnO on sleep and wakefulness is dependent on the behavioral state 
of the animal at the time of administration.  Microinjection of hypocretin-1 during 
wakefulness in cat (Moreno-Balandrán et al., 2008; Xi and Chase, 2009) and rat (Watson 
et al., 2008b) caused an increase in wakefulness, whereas microinjection of hypocretin-1 
during NREM sleep increased REM sleep (Xi et al., 2002).  Administration of 
hypocretin-1 during NREM sleep does not always cause an increase in REM sleep.  For 
example, microinjection of hypocretin-1 into the LDT or the locus coeruleus during 
NREM sleep caused an increase in wakefulness (Xi et al., 2001; Xi et al., 2002).   
Whether microinjection of hypocretin-1 into the LDT or the locus coeruleus during 
wakefulness will cause an increase in REM sleep is yet to be tested.   
The mechanism by which hypocretin-1 in the PnO promotes either wakefulness or 
REM sleep is not clear.  The increase in REM sleep caused by microinjection of 
hypocretin-1 into the PnO during NREM sleep is dependent on protein kinase C (PKC) 
activation (Xi and Chase, 2006).  Whether PKC activation is also important for the 
increase in wakefulness caused by hypocretin-1 during wakefulness is unknown.  The 
increase in wakefulness or REM sleep caused by hypocretin-1 is likely to involve the 
orchestration and coordination of multiple neurotransmitters in specific target neurons. 
The PnO expresses hcrt-r1 and hcrt-2 (Greco and Shiromani, 2001) and in vitro 
[35S] guanylyl 5´-(γ-thio) triphosphate ([35S] GTPγS) autoradiography demonstrates that 
both receptor subtypes are functional in the PnO (Bernard et al., 2003; Bernard et al., 
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2006).  Furthermore, autoradiography with [35S] GTPγS suggests that at least some 
hypocretin receptors in the PnO couple to inhibitory G proteins (Bernard et al., 2003; 
Bernard et al., 2006).  Recent immunohistochemical findings show that hypocretin 
receptors are present on GABAergic neurons in the PnO (Brischoux et al., 2008).  
Consistent with these findings is the observation that application of hypocretin-1 excites 
GABAergic neurons in the PnO (Nuñez et al., 2006; Brown et al., 2008).  Moreover, 
delivery of hypocretin-1 to the PnO via microdialysis causes an increase in GABA levels 
in the PnO (Watson et al., 2008b).  Together, these findings demonstrate that hypocretin-
1 and GABA interact in the PnO.  Whether or not the increase in wakefulness caused by 
hypocretin-1 (Moreno-Balandrán et al., 2008; Watson et al., 2008b; Xi and Chase, 2009) 
is dependent on GABAergic transmission is unknown.  In addition to GABA, hypocretin-
1 interacts with ACh in the PnO.  Microdialysis delivery of hypocretin-1 to the PnO 
increases ACh release in the PnO (Bernard et al., 2003, 2006) by unknown mechanisms.  
Glutamatergic transmission in the PnO 
Very little is known about glutamatergic regulation of sleep and wakefulness, and 
few studies have investigated the sleep-related effects of glutamate in the PnO.  
Immunohistochemical evidence demonstrates that approximately 50% of the pontine 
reticular formation neurons in cat show glutamate-like immunoreactivity (Lai et al., 
1999).  Electrophysiological studies demonstrate that glutamate excites pontine reticular 
formation neurons (Greene and Carpenter, 1985; Nuñez et al., 1998) by activating α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), kainate, or N-methyl-D-





The goal of my thesis research was to elucidate the mechanisms by which 
hypocretin-1 administered into the PnO causes an increase in wakefulness.  Specific 
Aims 1 and 2 tested the hypothesis that hypocretin receptors and GABAA receptors in the 
PnO mediate the increase in wakefulness induced by hypocretin-1.  Specific Aim 3 tested 
the hypothesis that ACh release in the PnO is modulated by glutamate.  
 
Specific Aim 1 demonstrated that microinjection of hypocretin-1 into the PnO 
causes a concentration-dependent increase in wakefulness. 
Several lines of evidence indicate that hypocretin-1 in the PnO is wakefulness 
promoting.  However, few studies have addressed whether the increase in wakefulness is 
receptor-mediated.  Both hcrt-r1 and hcrt-r2 are localized in the PnO, and hypocretin-1-
induced [35S]GTPγS binding is receptor-mediated (Bernard et al., 2003, 2006).  Whether 
the increase in wakefulness caused by hypocretin-1 is concentration-dependent was 
unknown prior to my studies.  Increasing concentrations of hypocretin-1 were 
administered to the PnO of rat and states of sleep and wakefulness were recorded. 
Chapter 2 reports the results from these experiments. 
This thesis research is the first to show that microinjection of hypocretin-1 into 
the PnO causes a concentration-dependent increase in wakefulness (Brevig et al., 2010).  
The increase in wakefulness was caused by decreasing the number and increasing the 
duration of wakefulness episodes.  Microinjection of hypocretin-1 into the PnO caused a 
concentration-dependent decrease in NREM sleep by decreasing the number and the 
duration of NREM sleep episodes.  As expected, hypocretin-1 produced a concentration-
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dependent decrease in REM sleep that was caused by decreasing the number of REM 
sleep episodes.  Lastly, hypocretin-1 decreased in the number of state transitions in a 
concentration-dependent manner.  Results from Aim 1 support the interpretation that the 
increase in wakefulness caused by hypocretin-1 is receptor-mediated.   
Specific Aim 2 determined that the hypocretin-1-induced increase in wakefulness is 
blocked by the hypocretin receptor-1 antagonist SB-334867 and the GABAA 
receptor antagonist bicuculline administered to the PnO. 
The results from Aim 1 suggested that the increase in wakefulness caused by 
hypocretin-1 is receptor-mediated.  Aim 2 further determined whether the hypocretin-1-
induced increase in wakefulness is mediated by hypocretin receptors.  The results are 
presented in Chapter 2.  The hcrt-r1 antagonist SB-334867 was co-administered with 
hypocretin-1 into the PnO and states of sleep and wakefulness were recorded.  The results 
from Aim 2 demonstrate that the increase in wakefulness was blocked by the hcrt-r1 
antagonist SB-334867 (Brevig et al., 2010).  Overall, these findings and those from Aim 
1 support the conclusion that activation of hypocretin receptors in the PnO increases 
wakefulness.  Future studies to determine whether microinjection of SB-34867 into the 
PnO causes a concentration-dependent decrease in wakefulness and increase in sleep will 
be important for determining whether endogenous hypocretin-1 in the PnO functions to 
promote wakefulness. 
The second hypothesis tested in Aim 2 was whether activation of GABAA 
receptors is important for mediating increase in wakefulness produced by hypocretin-1. 
In these studies hypocretin-1 and the GABAA receptor antagonist bicuculline were co-
administered into the PnO.  Bicuculline blocked the hypocretin-1-induced increase in 
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wakefulness, demonstrating that GABAergic transmission in the PnO is at least partly 
responsible for mediating the hypocretin-1-induced increase in wakefulness.  These 
results are presented in Chapter 2.  This is the first study to determine that GABAergic 
transmission is necessary for hypocretin-1-induced increase in wakefulness. 
Specific Aim 3 demonstrated that administration of glutamate into the PnO 
modulates ACh release in the PnO 
 The results presented in Aim 3 provide evidence that glutamate modulates ACh 
release in the PnO.  One possible mechanism by which glutamate alters sleep-wake states 
is by modulating ACh release in the PnO.  In vivo microdialysis and high performance 
liquid chromatography coupled with electrochemical detection were used in Chapter 3 
studies to detect and quantify ACh.  ACh release during dialysis with Ringer’s (control) 
was compared to ACh release during dialysis with glutamate.  Administration of 
glutamate to the PnO decreased ACh release in the PnO.  The results from Chapter 3 
were used to make implications about the neural circuitry in the PnO that causes the 
hypocretin-1-induced increase in ACh release.  Proposed synaptic models based on 
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WAKEFULNESS IS INCREASED BY GABAA-HYPOCRETIN RECEPTOR 
INTERACTION IN THE PONTINE RETICULAR FORMATION 
SUMMARY 
 
 Hypocretin-1/orexin A administered directly into the oral part of rat pontine 
reticular formation (PnO) causes an increase in wakefulness and extracellular GABA 
levels.  The receptors in the PnO that mediate these effects have not been identified.  
Therefore, this study tested the hypothesis that the increase in wakefulness caused by 
PnO administration of hypocretin-1 occurs via activation of GABAA receptors and 
hypocretin receptors. 
 Hypocretin-1 caused a significant, concentration dependent increase in 
wakefulness and decrease in rapid eye movement (REM) sleep and non-REM (NREM) 
sleep.  Co-administration of SB-334867 and hypocretin-1 blocked the hypocretin-1-
induced increase in wakefulness and decrease in both the NREM and REM phases of 
sleep.  Co-administration of bicuculline and hypocretin-1 blocked the hypocretin-1-
induced increase in wakefulness and decrease in NREM sleep caused by hypocretin-1.  
The increase in wakefulness caused by administering hypocretin-1 to the PnO is mediated 
by hypocretin receptors and GABAA receptors in the PnO.  These results show for the 






 The neuropeptides hypocretin-1 and hypocretin-2 (orexin A and orexin B) 
are synthesized exclusively by neurons in the lateral hypothalamic area (de Lecea et al., 
1998; Peyron et al., 1998; Sakurai et al., 1998). Hypocretin deficiency in humans 
underlies the pathophysiology of narcolepsy, (Peyron et al., 2000; Thannickal et al., 
2000) and disruption of hypocretin signaling in mouse (Chemelli et al., 1999), rat 
(Gerashchenko et al., 2001; Beuckmann et al., 2004), and dog (Lin et al., 1999) leads to 
narcolepsy-cataplexy. Hypocretinergic neurons project to multiple areas of the brain, 
including those important for regulating sleep and wakefulness (Peyron et al., 1998). One 
such area is the pontine reticular nucleus, oral part (PnO) (Peyron et al., 1998; Nuñez et 
al., 2006). The PnO is the rostral portion of the rodent pontine reticular formation 
(Paxinos and Watson, 2007) and contributes to the generation of wakefulness and rapid 
eye movement (REM) sleep (Lydic and Baghdoyan, 2005). Microinjection of hypocretin-
1 into rat PnO causes an increase in wakefulness (Watson et al., 2008), and 
microinjection of hypocretin-1 into cat pontine reticular formation increases the cortically 
activated states of REM sleep (Xi et al., 2002b) or wakefulness (Moreno-Balandrán et al., 
2008; Xi and Chase, 2009). 
Administering hypocretin-1 into the PnO may increase wakefulness by 
modulating the release of arousal-promoting neurotransmitters within the PnO. Direct 
administration of hypocretin-1 to the PnO of isoflurane-anesthetized rat causes a 
concentration-dependent increase in both acetylcholine (ACh) release (Bernard et al., 
2006) and GABA levels (Watson et al., 2008) within the PnO.  Extracellular recording 
studies of PnO neurons in urethane-anesthetized rat show that iontophoretic application 
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of hypocretin-1 causes a hyperpolarization that is blocked by prior application of 
bicuculline (Nuñez et al., 2006). This finding indicates that the hypocretin-1–induced 
inhibition of PnO neurons is mediated by GABAA receptors. Identified GABAergic 
neurons in brainstem slices of mouse PnO have been shown to be excited by hypocretin-1 
(Brown et al., 2008), and intracellular recording studies in halothane-anesthetized cat 
show that hypocretin-1 can also cause direct depolarization of PnO neurons and an 
increase in PnO neuronal firing rate (Xi et al., 2002b).  Numerous studies have 
demonstrated that GABAergic transmission in the PnO increases wakefulness and 
inhibits REM sleep (Camacho-Arroyo et al., 1991; Xi et al., 1999; Sanford et al., 2003; 
Chang et al., 2006; Flint et al., 2007; Marks et al., 2008; Vanini et al., 2008; Watson et 
al., 2008).  The present study provides the first test of the hypothesis that the 
wakefulness-promoting effects of delivering hypocretin-1 into the PnO are mediated by 
GABAA receptors as well as by hypocretin receptors. This hypothesis was evaluated by 
determining whether (1) microinjection of hypocretin-1 into the PnO causes a 
concentration-dependent increase in wakefulness, (2) this increase in wakefulness is 
blocked by coadministration of the hypocretin receptor-1 (hcrt-r1) antagonist SB-334867, 
and (3) coadministration of the GABAA receptor antagonist bicuculline also blocks the 
wakefulness response to hypocretin-1. Portions of these data have been presented as 
abstracts (Brevig et al., 2008, 2009). 
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MATERIALS AND METHODS 
 
Chemicals and Drug Solutions 
Human hypocretin-1 was purchased from California Peptide Research, Inc. 
(Napa, CA). Bicuculline methiodide was purchased from Sigma Aldrich (St. Louis, MO) 
and N-(2-Methyl-6-benzoxazolyl)-N″-1,5-naphthyridin-4-yl urea (SB-334867) was 
obtained from Tocris Bioscience (Ellisville, MO). Chemicals for Ringer solution (147.0 
mM NaCl, 2.4 mM CaCl2, 4.0 mM KCl, 1.0 mM MgSO4, pH 6.0) were acquired from 
Fisher Scientific (Pittsburgh, PA). All drugs used for the antagonist-blocking studies 
were dissolved in Ringer solution containing 2% dimethyl sulfoxide, which was 
purchased from Sigma Aldrich. Drug solutions used for intracranial microinjections were 
made immediately before use. 
Animals, Surgery, and Conditioning of Behavior 
Animal experiments were approved by the University of Michigan Committee on 
Use and Care of Animals and performed in accordance with the US Public Health Service 
Policy on Humane Care and Use of Laboratory Animals (National Institutes of Health 
Publication 80-23). Adult (235- to 310-g) male Crl:CD*(SD) (Sprague Dawley) rats (n  = 
23; Charles River Laboratories, Wilmington, MA) were housed with unlimited access to 
food and water and kept on a 12-hour light/dark cycle (lights on at 06:00). 
Procedures for surgical implantation of recording electrodes and a microinjection 
guide tube have been described in detail.(Watson et al., 2007; Watson et al., 2008) 
Briefly, rats were anesthetized with isoflurane (Abbott Laboratories, North Chicago, IL) 
and implanted with 3 screw electrodes (8IE36320SPCE, Plastics One, Roanoke, VA) for 
recording the cortical electroencephalogram (EEG). Three pair of EEG electrodes were 
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placed using the following stereotaxic coordinates relative to bregma: 1.0 mm anterior 
and 1.5 mm lateral, 2.0 mm posterior and 1.5 mm lateral, and 2.0 mm posterior and 1.27 
mm lateral. Two electrodes for recording the electromyogram (EMG) were implanted 
bilaterally in the dorsal neck muscles. EMG electrodes were assembled from AS632 
biomed wire (6 cm length; Cooner Wire Company, Chatsworth, CA) and electrical gold 
socket contacts (Plastics One, 8IE3630XXXXE). A guide cannula (8IC315GSPCXC, 
Plastics One) containing a stylet (8IC315DCXXXC, Plastics One) was aimed 3 mm 
above the left PnO at 8.40 mm posterior to bregma, 1.0 mm lateral to the midline, and 6.2 
mm below the skull surface (Paxinos and Watson, 2007).  Electrode leads were routed 
into a 6-pin electrode pedestal (MS363, Plastics One). Dental acrylic (Lang Dental 
Manufacturing Company, Inc., Wheeling, IL) and 3 anchor screws (MPX-0080-02PC-C, 
Small Parts, Inc., Miami Lakes, FL) were used to adhere the guide cannula, electrodes, 
and pedestal to the skull. 
Rats recovered from surgery for a minimum of 7 days, during which time they 
were conditioned to being handled for microinjections and to being tethered (363-441/6, 
Plastics One) in a recording chamber (Raturn; Bioanalytical Systems, West Lafayette, 
IN). To determine whether rats were adequately conditioned, a mock microinjection was 
performed by inserting and removing a microinjector (8IC315IXXXXC, Plastics One). 
EEG and EMG signals then were recorded for 2 hours. Rats were considered ready to 
enter the microinjection protocol when the latency to non-REM (NREM) sleep was less 
than 30 minutes. 
Microinjections and Quantification of Arousal States 
 The day before each microinjection, rats were placed in the recording chambers 
and tethered overnight. All microinjections were made between 09:30 and 10:30, and 
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microinjections into the same rat were separated by a minimum of 7 days. Microinjection 
volume (100 nL) and duration (1 min) were held constant for all drugs, and 2-hour 
electrophysiologic recordings were started immediately after injection. Two groups of 
rats were used for this study. The first group (n  = 14) received 0, 0.1, 1, 10, and 100 
pmol hypocretin-1 (0, 0.36, 3.56, 35.6, and 356 ng, respectively). The order in which the 
different concentrations of hypocretin-1 were administered was randomized, and not all 
animals received all concentrations. The second group of rats (n  = 9) was microinjected 
with Ringer solution containing 2% dimethyl sulfoxide (vehicle control), hypocretin-1 
(10 pmol), bicuculline (0.2 pmol; 0.1 ng) in combination with hypocretin-1 (10 pmol), or 
SB-334867 (10 pmol; 3.4 ng) in combination with hypocretin-1 (10 pmol). All rats in the 
second group received all 4 drug treatments. 
EEG and EMG recordings were scored manually in 10-second bins as 
wakefulness, NREM sleep, or REM sleep using Icelus Acquisition software (Opp, 1998).  
Previously described methods were used for amplification, digitization, and fast Fourier 
transform (FFT) analysis of signals (Watson et al., 2007; Watson et al., 2008).  Briefly, 
FFT plots were constructed by analyzing EEG signals in 0.5-Hz increments every 2 
seconds for frequencies ranging from 0.5 to 25.0 Hz. Five consecutive 2-second bins 
were averaged to produce 1 FFT for each 10-second epoch. Sample bins of 10 seconds in 
duration were averaged over five 1-minute intervals in the first hour following 
microinjection of Ringer solution and hypocretin-1 (100 pmol/100 nL). Sleep records 
were scored by 2 investigators, 1 of which was blinded to the treatment condition. 
Agreement between the 2 scores of greater than 90% was achieved for all records. 
Dependent measures included the percentage of time spent in wakefulness, NREM sleep, 
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and REM sleep; the average duration of the longest wakefulness episode from each 
recording; the average duration of NREM sleep and REM sleep episodes; the number of 
wakefulness, NREM sleep, and REM sleep episodes; the number of transitions; and the 
latency to onset of the first episode of NREM sleep and REM sleep. 
Histologic Verification of Microinjection Sites 
Rats were deeply anesthetized with isoflurane (5%) and decapitated. Brains were 
immediately removed, blocked, and frozen. The brainstem block was sectioned coronally 
from caudal to rostral using a cryostat (Leica Microsystems, Nussloch, Germany). Serial 
sections (40 microns thick) were slide mounted, dried, fixed in paraformaldehyde vapor 
(80°C), and stained with cresyl violet. Stained tissue sections and a 1-mm calibration bar 
were digitized using a Super Nikon Coolscan 4000 ED Film Scanner (Nikon Inc, 
Melville, NY). Microinjection sites were identified and assigned stereotaxic coordinates 
by comparison with a rat brain atlas (Paxinos and Watson, 2007).  
Statistical Analyses 
Data sets for all dependent measures were normally distributed. Therefore, data 
were evaluated by parametric tests and are reported as mean ± SEM. For the 
concentration-response study, the effects of hypocretin-1 on sleep and wakefulness were 
determined using a linear mixed model for a randomized incomplete block design. 
Concentration response data were fit to the equation Y = B+(T-B)/(1+10^((LogEC50-
X) HillSlope)), where B represents the lower limit for the dependent variable (eg, 
percentage of wakefulness), T is the upper limit for the dependent variable, X is the 
logarithm of the hypocretin-1 concentration, and Y is the dependent variable. Regression 
analyses were used to obtain the coefficient of determination (r2) and calculate the 
percentage of the response accounted for by the concentration of hypocretin-1 (r2  100). 
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For the antagonist-blocking study, drug effects on sleep and wakefulness were 
determined by 1-way analysis of variance (ANOVA) for repeated measures and Dunnett 
posthoc multiple comparisons test. Because there were so few REM sleep episodes in the 
first hour after injection, a Poisson regression with a Generalized Estimating Equations 
model was used to test for drug effects on the number of REM episodes. This approach 
takes into account the correlation among repeated observations from the same rat. Z-tests 
were used to determine significant effects, and Bonferroni correction was used for 
multiple comparisons between drug treatments. Statistical programs used included SAS 
(release 9.1.3, SAS Institute, Cary, NC) and GraphPad Prism v4.0c for Macintosh. 





Microinjection of hypocretin-1 into the PnO caused a concentration-dependent 
increase in wakefulness and decrease in sleep  
To determine whether the hypocretin-1–induced increase in wakefulness was 
mediated by hypocretin receptors, increasing concentrations of hypocretin-1 were 
microinjected into the PnO and the effects on sleep and wakefulness were quantified. 
Figure 2.1 shows that all microinjection sites used for the concentration-response study 
were localized to the PnO. The average stereotaxic coordinates (Paxinos and Watson, 
2007) for these injection sites were 7.9 ± 0.1 mm posterior to bregma, 8.6 ± 0.1 mm 
ventral to the top of the skull, and 1.1 ± 0.1 mm from the midline. Figure 2.2 illustrates 
the sequence of sleep and wakefulness from 2 representative rats in the first hour after 
PnO microinjection of 2 concentrations of hypocretin-1 relative to control (microinjection 
of Ringer solution). Hypocretin-1 increased the amount of time spent in wakefulness, 
decreased NREM sleep, and abolished REM sleep. 
Figure 2.3 summarizes the group data for the first hour after injection. ANOVA 
revealed a significant concentration main effect of hypocretin-1 on the percentage of time 
spent in wakefulness (Figure 2.3A; F4,32 = 6.51; p = 0.0006), NREM sleep (Figure 2.3B; 
F4,32 = 6.37; p = 0.0007), and REM sleep (Figure 2.3C; F4,32 = 4.68; 32; p = 0.004) and on 
the number of episodes of wakefulness (Figure 2.3D; F4,32 = 3.33; p = 0.02) and NREM 
sleep (Figure 2.3E; F4,32 = 3.38; p = 0.02). The effect of hypocretin-1 on the number of 
REM sleep episodes approached significance (Figure 2.3F; z = 9.04, p = 0.06). There was 
a significant concentration main effect on the duration of the longest wakefulness episode 
(Figure 2.3G; F4,32 = 6.85; p = 0.0004) and on the average duration of NREM sleep 
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episodes (Figure 2.3H; F4,30 = 2.75; p = 0.046). There was no significant change in the 
average duration of REM-sleep episodes (Figure 2.3I). Microinjection of hypocretin-1 
into the PnO caused a significant concentration-dependent effect on the latency to onset 
of NREM sleep (Figure 2.3J; F4,32 = 29.81; p < 0.0001) and REM sleep (Figure 2.3K; 
F4,21 =  2.97; p = 0.043). Consistent with these effects, the number of state transitions 
varied significantly as a function of hypocretin-1 concentration (Figure 2.3L; F4,32 = 3.38; 
p = 0.02). All dependent measures except for the percentage of time spent in REM sleep 
returned to control levels in the second hour after injection (data not plotted). REM sleep 
remained decreased (F4,32 = 2.75; p = 0.048) following microinjection of 100 pmol of 
hypocretin (p < 0.01). FFT analysis of EEG signals recorded from 8 rats during the first 
hour after microinjection showed that, compared with an injection of Ringer solution, 




Figure 2.1.  All concentrations of hypocretin-1 were injected into the pontine reticular 
nucleus, oral part (PnO).  Microinjection sites (n=14) from the concentration response 
experiments are represented as black dots on five coronal atlas plates (modified from 
Paxinos and Watson, 2007).  Numbers on the right side of each plate indicate mm 
posterior to bregma.  The sagittal drawing of the rat brain (upper right) contains vertical 
lines that designate the anterior to posterior range of the microinjection sites, which 
spanned from 7.6 to 8.3 mm posterior to bregma.  The digitized image of a cresyl violet 




Figure 2.2.  Representative time-course plots of wakefulness and sleep are shown for the 
first hour after microinjection of Ringer solution (vehicle control) or hypocretin-1 (Hcrt-
1) into the pontine reticular nucleus, oral part (PnO).  The height of the bars indicates the 
sequence of wakefulness (lowest bars), non-rapid eye movement sleep (NREM) 
(intermediate bars), and rapid eye movement sleep (REM) (highest bars). Each column 









Figure 2.3.  Significant concentration-dependent changes in sleep and wakefulness were 
caused by microinjection of hypocretin-1 into the pontine reticular nucleus, oral part 
(PnO). Data from 14 rats are plotted for the first hour after injection. Dunnett multiple 
comparisons tests indicated significant (* p ≤ 0.05) differences from control (0 pmol/100 
nL). For all data sets except rapid eye movement sleep (REM) duration (I), coefficients of 
determination (r2) indicated the percentage of the variability accounted for by the 
concentration of hypocretin-1 was: (A) 98%; (B) 97%; (C) 93%; (D) 91%; (E) 90%; (F) 





Both the hypocretin receptor-1 antagonist SB-334867 and the GABAA receptor 
antagonist bicuculline blocked the hypocretin-1–induced increase in wakefulness  
To further investigate whether the hypocretin-1–induced increase in wakefulness 
was mediated by hypocretin receptors, sleep and wakefulness were quantified after 
coadministering SB-334867 and hypocretin-1. This study also coadministered bicuculline 
and hypocretin-1 to determine whether GABAergic transmission in the PnO contributed 
to the hypocretin-1–induced increase in wakefulness. Figure 2.4 documents that all 
microinjection sites used for the blocking studies were localized to the PnO. The mean 
stereotaxic coordinates were 7.9 ± 0.1 mm posterior to bregma, 8.9 ± 0.1 mm ventral to 
the top of the skull, and 1.0 ± 0.1 from the midline. There was no significant difference 
between the stereotaxic coordinates of injection sites used for the concentration-response 
study (Figure 2.1) and the receptor-antagonist study (Figure 2.4).  
Figure 2.5 plots the time course of wakefulness and sleep recorded from 2 
representative rats during the first hour after microinjection of Ringer solution (Figure 
2.5A and 2.5E), hypocretin-1 (10 pmol) (Figure 2.5B and 2.5F), SB-334867 (10 pmol) + 
hypocretin-1 (10 pmol) (Figure 2.5C and 2.5G), and bicuculline (0.2 pmol) + hypocretin-
1 (10 pmol) (Figure 2.5D and 2.5H). The hypocretin-1–induced increase in wakefulness 
and decrease in NREM sleep (Figure 2.5B and 2.5F) were blocked by coadministration of 
SB-334867 (Figure 2.5C and 2.5G) and by coadministration of bicuculline (Figure 2.5D 
and 2.5H). SB-334867 also antagonized the decrease in REM sleep (Figure 2.5C and 
2.5G), whereas bicuculline did not block the REM-sleep inhibition caused by hypocretin-
1 (Figure 2.5D and 2.5H).  
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 The group data are summarized in Figure 2.6. ANOVA revealed that, in the first 
hour after injection, the percentage of time spent in wakefulness (Figure 2.6A, F3,24 = 
5.44; p = 0.005) and NREM sleep (Figure 2.6B, F3,24 = 4.44; p = 0.01) varied as a 
function of drug treatment. The hypocretin-1–induced increase in the percentage of time 
spent in wakefulness was blocked by coadministration of either SB-334867 or bicuculline 
(Figure 2.6A). The decrease in NREM sleep time was reversed by SB-334867 and by 
bicuculline (Figure 2.6B). A repeated-measures ANOVA adjusted for unequal variances 
revealed that the percentage of time spent in REM sleep varied significantly as a function 
of drug treatment (Figure 2.6C, F3,24 = 6.03; p = 0.003). The hypocretin-1–induced 
decrease in REM sleep was partially reversed by SB-334867 but was not blocked by 








Figure 2.4. SB-334867 and bicuculline were injected into the pontine reticular nucleus, 
oral part (PnO). Microinjection sites (n = 9) from the antagonist-blocking studies are 
represented as black dots on 5 coronal atlas plates (modified from Paxinos and Watson, 
2007). Numbers on the right side of each plate specify mm posterior to bregma. The 
vertical lines in the sagittal drawing (upper right) indicate that the microinjection sites 
spanned from 7.5 to 8.6 mm posterior to bregma. One representative microinjection site 






Figure 2.5.  Temporal organization of wakefulness and sleep in the first hour after 
microinjection of Ringer solution (A and E), 10 pmol of hypocretin-1 (B and F), 10 pmol 
of SB-334867 (SB) + 10 pmol of hypocretin-1 (Hcrt-1) (C and G), and 0.2 pmol of 
bicuculline (Bic) + 10 pmol of Hcrt-1 (D and H) into the pontine reticular nucleus, oral 
part (PnO). Each column shows data from 1 rat. Bar height indicates wakefulness (lowest 
bars), non-rapid eye movement sleep (NREM) (intermediate bars), and rapid eye 













Figure 2.6.  Coadministration of SB-334867 (SB) or bicuculline (Bic) blocked the 
increase in wakefulness and decrease in non-rapid eye movement (NREM) sleep caused 
by hypocretin-1 (Hcrt-1). Data represent measures from 9 rats during the first hour after 
injection. Dunnett multiple comparisons tests indicated significant (*p ≤ 0.05) differences 







The present study reports, for the first time, that microinjection of hypocretin-1 
into the PnO of awake rat caused a concentration-dependent increase in wakefulness that 
was blocked by coadministration of a hcrt-r1 antagonist. These findings demonstrate that 
the PnO is one brain region where activating hypocretin receptors can promote 
wakefulness. An additional novel finding is that the hypocretin-1–induced increase in 
wakefulness was prevented by administering the GABAA receptor antagonist bicuculline 
into the PnO. Considered with data showing that delivering hypocretin-1 to the PnO 
increases GABA levels in the PnO (Watson et al., 2008) and causes inhibition of some 
PnO neurons (Nuñez et al., 2006), and with evidence that GABAergic transmission in the 
PnO is wakefulness promoting (Camacho-Arroyo et al., 1991; Xi et al., 1999; Sanford et 
al., 2003; Chang et al., 2006; Flint et al., 2007; Marks et al., 2008; Vanini et al., 2008; 
Watson et al., 2008), the present results support the interpretation that increasing 
GABAergic transmission in the PnO is one mechanism by which hypocretin-1 increases 
wakefulness. The results are discussed below relative to the functional roles of 
hypocretin-1 in rat PnO and the mechanisms by which hypocretin-1 administered to the 
PnO causes an increase in wakefulness. Limitations of the present study are also 
considered. 
What are the functional roles of hypocretin-1 in the PnO? 
 The hypocretin peptides have multiple functional roles, one of which is to 
maintain wakefulness (Ohno and Sakurai, 2008).  PnO neurons participate in generating 
the cortical activation of wakefulness and REM sleep (Steriade and McCarley, 2005), and 
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microinjection of hypocretin-1 into rat PnO was recently shown to increase the amount of 
wakefulness (Watson et al., 2008).  Determining concentration dependence and 
antagonist blocking are established approaches for revealing whether or not responses are 
receptor mediated (Norman, 1979).  The present study provides data fulfilling the criteria 
of concentration dependence (Figure 2.3) and antagonist blocking (Figure 2.6), indicating 
that hypocretin-1 acts at its receptors in the PnO to increase wakefulness. 
Efforts to elucidate functions of hypocretin-1 also have found that microinjecting 
hypocretin-1 into rat PnO causes an antinociceptive response that is blocked by 
coadministration of the hcrt-r1 antagonist SB-334867 (Watson et al., 2010).  This result 
demonstrates that the antinociceptive response is mediated by hypocretin receptors. 
Furthermore, blocking hypocretin receptors in the PnO with SB-334867 in the absence of 
exogenous hypocretin-1 increases nociceptive responsiveness to a thermal stimulus 
(Watson et al., 2010).  This finding means that endogenous hypocretin-1 in rat PnO is 
antinociceptive.  Microdialysis delivery of hypocretin-1 to rat PnO increases ACh release 
(Bernard et al., 2006), and ACh in the PnO of cat (Kshatri et al., 1998) and mouse (Wang 
et al., 2009) is antinociceptive. Future studies can determine whether the antinociceptive 
effects of hypocretin-1 in rat PnO depend on cholinergic transmission. 
By what mechanisms does hypocretin in the PnO increase wakefulness?  
 Hypocretins are excitatory (de Lecea et al., 1998), and one mechanism by which 
these peptides are thought to enhance arousal is to activate neurons that drive 
wakefulness (Tsujino and Sakurai, 2009), thus increasing the release of wakefulness-
generating neurotransmitters. Hypocretin-1 delivered to the PnO increases local GABA 
levels, and GABA in the PnO increases wakefulness (reviewed in Vanini et al., 2010). 
Pharmacologically increasing GABA levels in the PnO increases wakefulness (Watson et 
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al., 2008), and endogenous GABA levels in the PnO are significantly greater during 
wakefulness than during REM sleep (Vanini et al., 2009).  GABA levels in the PnO are 
also greater during wakefulness than during the loss of consciousness produced by the 
general anesthetic isoflurane (Vanini et al., 2008).  Furthermore, loss of endogenous 
hypocretin increases recovery time from isoflurane anesthesia (Kelz et al., 2008).  The 
present finding that the hypocretin-1–induced increase in wakefulness was blocked by 
coadministration of bicuculline (Figure 2.6) demonstrates that the wakefulness response 
is mediated by GABAA receptors. This finding, therefore, supports the interpretation that 
the hypocretin-1–induced increase in wakefulness (Figure 2.3) results from enhanced 
GABAergic transmission in the PnO. 
When given systemically to humans or animals, drugs that increase GABAergic 
transmission produce behavioral states such as sleep (Winsky-Sommerer, 2009) or 
general anesthesia (Franks, 2008).  The mechanisms by which GABAergic drugs cause a 
loss of waking consciousness are not fully understood but are likely to include inhibition 
of wakefulness-promoting neurons. For example, the hypnotic eszopiclone may cause 
sleep by potentiating transmission at GABAA receptors on pedunculopontine tegmental 
neurons (Ye and Garcia-Rill, 2009).  The mechanisms by which enhancing GABAergic 
transmission locally in the PnO causes an increase in wakefulness remain to be 
elucidated. Increased wakefulness is also caused by administering GABAergic drugs 
directly into the preoptic area/anterior hypothalamus (Lin et al., 1989) or the midbrain 
reticular formation (Tsuchiya and Fukushima, 1977).  Increased sleep, however, is caused 
by delivering a GABAA receptor agonist directly into the posterior hypothalamus (Lin et 
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al., 1989).  Therefore, GABAmimetics have opposite effects on sleep and wakefulness 
depending upon their site of action in the brain (Watson et al., 2008). 
Hypocretin-1 increases ACh release in the PnO (Bernard et al., 2006), and 
increasing cholinergic transmission in the PnO may contribute to the mechanism by 
which PnO administration of hypocretin-1 increases wakefulness. Cholinergic 
transmission in the PnO promotes the EEG activation characteristic of both wakefulness 
and REM sleep (Lydic and Baghdoyan, 2005; Steriade and McCarley, 2005).  Future 
studies are required to determine whether the increase in wakefulness caused by 
delivering hypocretin-1 into the PnO can be blocked by coadministering a cholinergic 
receptor antagonist. 
The hypocretin-1–induced increase in wakefulness was comprised of an increase 
in the duration of the longest wakefulness episode and a decrease in the number of 
wakefulness episodes (Figure 2.3). The increase in wakefulness was accompanied by a 
decrease in NREM sleep and REM sleep. EEG power was not altered by hypocretin-1, 
demonstrating similarity to spontaneously occurring wakefulness, NREM sleep, and 
REM sleep with respect to the trait of EEG activity. Hypocretin-1 decreased the 
percentage of time spent in NREM sleep by decreasing both the number and duration of 
NREM sleep episodes. The hypocretin-1–induced consolidation of wakefulness into 
longer episodes and the decrease in the number of state transitions is consistent with the 
finding that narcoleptic patients (Taheri et al., 2002; Scammell, 2003) and mice lacking 
hypocretin (Mochizuki et al., 2004; Zhang et al., 2007) show fragmentation of sleep and 
wakefulness. These results also support a recent modeling study predicting that 
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hypocretin-1 preferentially acts on long episodes of wakefulness (Diniz Behn et al., 
2008). 
Effects of hypocretin-1 on wakefulness varies with behavioral state and 
microinjection site 
 The sleep-wake response to microinjecting hypocretin-1 into cat pontine reticular 
formation depends on the behavior state of the cat when the drug is administered, the site 
of injection within the pontine brainstem, and the amount of hypocretin-1 injected. 
Microinjecting hypocretin-1 (125 pmol/250 nL; 450 ng) into the oral part of cat pontine 
reticular formation during NREM sleep increases REM sleep (Xi et al., 2002a), whereas 
administering hypocretin-1 (125 pmol/250 nL; 450 ng) into the same region during 
wakefulness produces an increase in wakefulness (Xi and Chase, 2009).  Microinjection 
of hypocretin-1 (2 to 20 pmol/20 nL; 7 to 71 ng) into a more dorsal region of cat pontine 
reticular formation (referred to as peri-locus coeruleus α) during wakefulness causes a 
concentration-dependent increase in wakefulness and decrease in NREM sleep and REM 
sleep, whereas the same concentrations of hypocretin-1 delivered to the ventral part of cat 
pontine reticular formation cause a selective inhibition of REM sleep and no change in 
the amount of wakefulness or NREM sleep (Moreno-Balandrán et al., 2008).  The 
dissimilar findings between these 2 studies in cat are reconciled by noting that different 
brain regions were microinjected with different amounts of hypocretin-1 in different 
microinjection volumes (Xi et al., 2002a; Moreno-Balandrán et al., 2008). 
Species-specific responses to PnO microinjection of hypocretin-1 in rat and cat 
have been discussed in detail (Watson et al., 2008).  For the present report and a previous 
study (Watson et al., 2008) using rat, all microinjections were made during wakefulness, 
and hypocretin-1 caused an increase in wakefulness (Figure 2.3). Rat microinjection sites 
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in the present study (Figures 2.1 & 2.4) are in homologous regions of cat pontine reticular 
formation that produced either increases in wakefulness when hypocretin-1 was injected 
during wakefulness (Xi and Chase, 2009) or selective decreases in REM sleep (Moreno-
Balandrán et al., 2008).  Hypocretin-1 did significantly decrease REM sleep in the 
present study and also decreased NREM sleep (Figure 2.3). The reasons for these 
differences are not known but could include differences in microinjection sites, 
hypocretin receptors, and afferent hypocretin terminals, in addition to the use of different 
microinjection volumes and amounts of hypocretin-1. 
Limitations, Conclusions, and Potential Clinical Significance 
 One unexplained finding of the present study is that bicuculline did not block the 
hypocretin-1–induced decrease in the amount of REM sleep (Figure 2.6C). This finding 
was unexpected because bicuculline alone delivered to the PnO of rat (Sanford et al., 
2003; Marks et al., 2008), cat (Xi et al., 1999; Vazquez and Baghdoyan, 2004), and 
mouse (Chang et al., 2006) increases REM sleep. Pontine reticular formation 
administration of bicuculline increases local ACh release (Vazquez and Baghdoyan, 
2004), and the increase in REM sleep that occurs by administering GABAA receptor 
antagonists to the PnO is blocked by the muscarinic cholinergic antagonist atropine 
(Marks et al., 2008).  Hypocretin-1 also increases ACh release in the PnO (Bernard et al., 
2006), and PnO administration of cholinomimetics significantly increases REM sleep 
(reviewed in Lydic and Baghdoyan, 2008).  These data support the interpretation that 
GABAergic transmission in the PnO inhibits REM sleep, in part, by inhibiting ACh 
release. A higher concentration of bicuculline or a GABAB receptor antagonist may be 
required to reverse the hypocretin-1–induced decrease in REM sleep. 
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The experiments reported here did not identify the hypocretin receptor subtype or 
subtypes in the PnO that mediate the wakefulness response to PnO administration of 
hypocretin-1 (Figure 2.3). Hypocretins signal through two subtypes of GPCRs, hcrt-r1 
and hcrt-r2, also called OX1R and OX2R (reviewed in Ohno and Sakurai, 2008). Hcrt-r1 
is selective for hypocretin-1, whereas hcrt-r2 does not distinguish between hypocretin-1 
and hypocretin-2 (Sakurai et al., 1998).  Rat PnO contains both hypocretin receptor 
subtypes (Greco and Shiromani, 2001), and hcrt-r1 and hcrt-r2 in the PnO each contribute 
to the hypocretin-induced increase in ACh release within the PnO (Bernard et al., 2006).  
Hcrt-r2 is present on GABAergic neurons in rat PnO (Brischoux et al., 2008), suggesting 
that hcrt-r2 mediates the increase in PnO GABA levels caused by hypocretin-1 (Watson 
et al., 2008), as well as the hypocretin-1–induced hyperpolarization of PnO neurons 
(Nuñez et al., 2006).  SB-334867 has a 50-fold higher affinity for hcrt-r1 than for hcrt-r2 
(Duxon et al., 2001), and the finding that the hypocretin-1–induced increase in 
wakefulness was blocked by SB-334867 (Figure 2.6A) supports the interpretation that the 
wakefulness response was mediated by hcrt-r1. Coadministration of SB-334867 did not 
return REM sleep to control levels (Figure 6C), suggesting that hcrt-r2 may mediate the 
decrease in REM sleep.  
Data from the present study (Figures 2.3 & 2.6) demonstrate that exogenous 
hypocretin-1 activates hypocretin receptors in rat PnO to increase and consolidate 
wakefulness. Whether endogenous hypocretin in rat PnO normally functions to promote 
wakefulness awaits the demonstration that antagonizing hypocretin receptors in the PnO 
causes a concentration-dependent decrease in wakefulness. 
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Despite the limitations discussed above, the present data show for the first time 
that activating hypocretin receptors in rat PnO causes an increase in wakefulness that is 
mediated by GABAergic transmission at GABAA receptors. This novel finding 
demonstrates that hypocretinergic and GABAergic transmission can interact in the 
pontine reticular formation to increase wakefulness. An extensive body of evidence 
supports the interpretation that one physiologic role of hypocretins is to maintain 
wakefulness (reviewed in Ohno and Sakurai, 2008). Neuronal systems regulating sleep 
and wakefulness are anatomically distributed and neurochemically heterogeneous, and 
the present data suggest that the PnO is one region where hypocretin-1 and GABA 
interact to increase periods of uninterrupted wakefulness and inhibit sleep. In addition to 
its wakefulness-promoting actions, hypocretin-1 has antinociceptive effects (Bingham et 
al., 2001), which also can be evoked from the PnO (Watson et al., 2010).  Opioids are the 
most widely used drugs for the treatment of pain, and negative side effects include 
disruption of the sleep-wake cycle (Lydic and Baghdoyan, 2007).  GABA levels in the 
PnO are decreased by opioids (Watson et al., 2007) and increased by hypocretin-1 
(Watson et al., 2008). Studies of GABAA-receptor point-mutated mice showing that 
systemic alterations of transmission at GABAA receptors can be antinociceptive 
(Zeilhofer et al., 2009) encourage continuing efforts to localize GABAergic modulation 
of nociception to specific brain regions. The present demonstration of a wakefulness-
promoting interaction between hypocretinergic and GABAergic neurotransmission in the 
PnO indicates the importance of determining whether coadministering hypocretin 
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GLUTAMATE ADMINISTERED TO RAT PONTINE RETICULAR NUCLEUS, 




 Immunohistochemical studies have indicated that neurons in the pontine reticular 
nucleus, oral part (PnO) are immunopositive for glutamate (Kaneko et al., 1989; Lai et 
al., 1999).  Maximal glutamate levels in the PnO occur during wakefulness (Watson et 
al., 2008), suggesting a causal link between glutamate release in the PnO and the 
generation of wakefulness.  ACh is a principal modulator of sleep and wakefulness and a 
number of studies show that cholinergic transmission in the PnO increases REM sleep or 
wakefulness (revewied in Lydic and Baghdoyan, 2008).  To further understand the 
neurochemical mechanisms by which glutamate in the PnO affects sleep-wake states, in 
vivo microdialysis was used to test the hypothesis that glutamate modulates ACh release 
in the PnO.  Dialysis delivery of glutamate caused a decrease in ACh release in the PnO.  
The findings presented here are consistent with the interpretation that one mechanism by 
which glutamate alters sleep and wakefulness is by modulating cholinergic transmission 






 Glutamate is the major excitatory neurotransmitter in the mammalian central 
nervous system yet little is known about the role of glutamate in sleep cycle control.  
State-dependent changes in glutamate levels suggest that depending on the brain area, 
glutamate promotes either wakefulness or REM sleep (Brevig and Baghdoyan, 2010).  
Administration of the glutamate agonist kainate into the dorsal raphe (Sakai and Crochet, 
2001) or the periaqueductal gray (Crochet et al., 2006) causes an increase in wakefulness.  
Depending on the dose, glutamate causes either an increase in REM sleep or an increase 
in wakefulness when microinjected into the pedunculopontine tegmental nucleus (PPT) 
(Datta and Siwek, 1997; Datta et al., 2001a).  One brain area that contributes to the 
generation of wakefulness and REM sleep is the PnO (Lydic and Baghdoyan, 2005).  The 
biosynthetic enzyme for glutamate, glutaminase, was immunohistochemically localized 
to the reticular formation (Kaneko et al., 1989), and approximately 50% of pontine 
reticular formation neurons in cat show glutamate-like immunoreactivity (Lai et al., 
1999).  Glutamate excites pontine reticular formation neurons (Greene and Carpenter, 
1985; Nuñez et al., 1998) and intracellular recordings demonstrate that the PnO contains 
functional α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), kainate, and 
N-methyl-D-aspartic acid (NMDA) receptors (Stevens et al., 1992).  Few studies have 
investigated the role of glutamate in the PnO in regulating sleep and wakefulness.  The 
levels of glutamate in rat PnO are higher during wakefulness than during sleep (Watson 
et al., 2008).  Administration of the glutamate agonists kainate and AMPA, but not 
NMDA, into a region dorsal to the PnO (peri-locus coeruleus alpha) causes an increase in 
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REM sleep (Onoe and Sakai, 1995).  Taken together these findings suggest that 
glutamatergic transmission in the PnO might increase wakefulness or REM sleep.   
One possible mechanism by which glutamate in the PnO modulates wakefulness 
and REM sleep is by modulating ACh release.  Several lines of evidence indicate that 
ACh is a principal modulator of sleep-wake states (reviewed in Lydic and Baghdoyan, 
2008).  Spontaneous ACh release in the cortex is high when the cortex is activated, such 
as during REM sleep and wakefulness (Marrosu et al., 1995).  ACh release in the pontine 
reticular formation is significantly increased during REM sleep (Kodama et al., 1990; 
Leonard and Lydic, 1995, 1997), and administration of cholinomimetics to the pontine 
reticular formation causes a REM sleep-like state (Baghdoyan et al., 1984b; Baghdoyan 
et al., 1984a, 1987; Baghdoyan et al., 1989; Imeri et al., 1994; Bourgin et al., 1995; 
Marks and Birabil, 1998, 2007).  
A number of studies show that glutamate modulates ACh release, and depending 
on the brain region glutamate agonists cause either an increase (Kurosawa et al., 1989; 
Giovannini et al., 1995; Ikarashi et al., 1998; Moor et al., 1998; Fournier et al., 2004) or a 
decrease (Giovannini et al., 1995; Materi and Semba, 2001; Neigh-McCandless et al., 
2002; Hernandez et al., 2003; Del Arco et al., 2008) in ACh release.  Both systemic 
administration and microdialysis delivery of a NMDA receptor antagonist to cat pontine 
reticular formation cause a decrease in ACh release in cat pontine reticular formation 
(Lydic and Baghdoyan, 2002).  These findings suggest that glutamate modulates ACh 
release in cat pontine reticular formation.  The present study tested the hypothesis that 
microdialysis delivery of glutamate to rat PnO modulates ACh release in the PnO.  
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MATERIALS AND METHODS 
 
Chemicals and Animals 
Glutamate (Fluka Biochemika Buchs, Switzerland) was dissolved in Ringer’s 
solution (147 mM NaCl, 2.4 mM CaCl2, 4.0 mM KCl, 10 µM neostigmine bromide 
(Sigma-Aldrich, St. Louis, MO), pH 5.8-6.2).  Salts for Ringer’s solution were acquired 
from Fisher Scientific (Pittsburgh, PA).  Animal experiments were approved by the 
University of Michigan Committee on Use and Care of Animals.  Adult (235 to 250 g) 
male Crl:CD*(SD) (Sprague Dawley) rats (n=5; Charles River Laboratories, Wilmington, 
MA) were housed with unlimited access to food and water and kept on a 12-hour 
light/dark cycle (lights on at 0600).  
Surgical preparation, microdialysis, and high performance liquid chromatography 
with electrochemical detection. 
 
 The time-course of the dialysis experiments is shown schematically in Figure 
3.1A.  Rats were anesthetized with 3.0% isoflurane (Abbott Laboratories, North Chicago, 
IL) in O2 and placed in a Kopf Model 962 small animal stereotaxic instrument with a 
Model 920 rat anesthesia mask (David Kopf Instruments, Tujunga, CA).  Following 
placement in the stereotaxic instrument, the delivered isoflurane concentration was 
decreased to 1.8 %.  A water blanket kept at 37◦C was used to maintain core body 
temperature.  The core body temperature and delivered isoflurane concentration were 
measured using a CardiocapTM/5 monitor (Datex-Ohmeda, Madison, WI).  A scalp 
incision was made to expose the skull and a craniotomy for the CMA/11 dialysis probe 
(cuprophane membrane, 1 mm in length, 0.24 mm in diameter, 6 kDA cut-off; DMA 
Microdialysis, North Chelmsford, MA) was made at stereotaxic coordinates 8.4 mm 
anterior to bregma and 1.0 mm lateral to the midline (Paxinos and Watson, 2007).  
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Following insertion of the dialysis probe, the delivered concentration of isoflurane was 
reduced to 1.5 % and held constant for the remainder of the experiment.  The levels of 
ACh were allowed to stabilize before collecting control samples.  The microdialysis 
probe was perfused continuously with Ringer’s solution (vehicle control) at a constant 
2.0 µl/min flow rate.  Five control samples (25 µl/12.5 minutes per dialysis sample) were 
collected during dialysis with Ringer’s solution before glutamate delivery was initiated 
by turning a CMA/110 liquid switch.  Five dialysis samples were collected during 
microdialysis with glutamate (1 mM).  CMA/11 dialysis probes are estimated to deliver 
5% of the dialysate drug concentration, and in the present study the estimated 
concentration of glutamate delivered to the PnO was approximately 500 µM.  After the 
collection period, the scalp wound was closed using sutures.  The animal was placed in a 
cage and kept under a heat lamp until ambulatory. 
 The percent of ACh recovered by the dialysis probe was determined in vivo 
before and after every experiment.  The dialysis probe was placed in a solution of known 
ACh concentration and five dialysis samples were collected and analyzed for ACh.  The 
pre- and post-experiment probe recoveries were calculated and only experiments in 
which pre and post-experiment probe recoveries did not change significantly in the 
direction of the drug effect were included into the final data set. 
Quantification of ACh 
 Each dialysis sample was injected into a high performance liquid chromatography 
system (Bioanalytical Systems, West Lafayette, IN) and carried through the system in 50 
mM Na2HPO4 mobile phase (pH 8.5) at a flow rate of 1 ml/min.  ACh was converted 
proportionally into hydrogen peroxide by an immobilized enzyme reactor column.  The 
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hydrogen peroxide was detected by a platinum electrode (+0.5 V applied potential) in 
reference to an Ag+/AgCl electrode.  The chromatographic signal was digitized and 
quantified using ChromoGraph software (Bioanalytical Systems).  The amount of ACh in 
each dialysis sample was determined by comparing chromatographic peak area produced 
by the dialysis sample to a seven point standard curve (0.05-1.0 pmol).  Differences in 
ACh before and during glutamate administration were evaluated using a paired two-tailed 
t-test.    
Histological identification of dialysis probe sites 
Three days after microdialysis experiments, rats were deeply anesthetized with 
isoflurane (5%) and decapitated.  Brains were immediately removed, frozen, and 
sectioned coronally (40 microns thick) from caudal to rostral using a cryostat (Leica 
Microsystems, Nussloch, Germany).  Serial sections were slide mounted, dried, fixed in 
paraformaldehyde vapor (80◦C), and stained with cresyl violet.  Stained tissue sections 
and a 1 mm calibration bar were digitized using a Super Nikon Coolscan 4000 ED Film 
Scanner (Nikon Inc, Melville, NY, USA).  Microdialysis probe sites were identified and 
assigned stereotaxic coordinates by comparison with a rat brain atlas (Paxinos and 





Microdialysis delivery of glutamate to the pontine nucleus oral part (PnO) 
decreased ACh release in the PnO  
 The effect of glutamate on ACh release is shown in Figure 3.1B-C.  Figure 3.1B 
illustrates the time-course of ACh release during one typical experiment.  Each bar 
represents sequential ACh samples collected for 12.5 minutes.  Figure 3.1C summarizes 
data from five microdialysis experiments.  Glutamate significantly decreased ACh release 
by an average of 23.5 % (t=5.0, df=4, p=0.007).  Histological data confirming that all 
dialysis sites were restricted to the PnO are shown in Figure 3.2.  The average stereotaxic 
coordinates (Paxinos and Watson, 2007) for these injection sites were 8.3±0.2 mm 






Figure 3.1.  Dialysis delivery of glutamate into the PnO decreased ACh release.  (A) 
Schematic timeline of microdialysis experiments.  The experimental manipulations are 
shown on the top row and the bottom row designates when the dependent measure was 
acquired.  (B) Time course of the glutamate-induced decrease in ACh release from one 
representative microdialysis experiment.  Each bar represents ACh levels plotted in 
sequential 12.5 minute intervals.  Hatched bars indicate ACh content in samples collected 
during dialysis with Ringer’s (control) and solid bars represent ACh release during 
dialysis with glutamate.  (C) Data were averaged across time for control (Ringer’s) 
samples and for glutamate samples for each experiment, and then across experiments 






Figure 3.2.  All microdialysis sites were located in the PnO.  Microdialysis sites (n=5) 
are represented as cylinders on three coronal atlas plates (modified from (Paxinos and 
Watson, 2007)).  Each cylinder is drawn to scale and corresponds to the 1 mm length and 
0.24 mm diameter of the dialysis probe membrane.  Numbers on the right side of each 
plate indicate mm posterior to bregma.  The cresyl violet stained section from one rat 
illustrates a representative dialysis probe site in the PnO.  The most ventral portion of the 








The present study shows that microdialysis delivery of glutamate to rat PnO 
caused a decrease in ACh release in the PnO. The present results encourage future studies 
aiming to identify which glutamate receptor subtypes modulate ACh release in the PnO.  
Future experiments could also determine whether glutamate in the PnO causes a 
concentration-dependent decrease in ACh release.  In order to address whether 
endogenous glutamate modulates ACh in the PnO, future studies may use glutamate 
receptor antagonists.  
Role of glutamate receptor subtypes in modulating ACh release 
Few studies have investigated the relative importance of specific glutamate 
receptor subtypes in modulating ACh release.  Blockade of NMDA receptors in the 
pontine reticular formation of isoflurane-anesthetized cat caused a decrease in ACh 
release in the pontine reticular formation (Lydic and Baghdoyan, 2002).  These findings 
suggest that activation of NMDA receptors might cause an increase in ACh release in the 
pontine reticular formation.  Although the present and previous (Lydic and Baghdoyan, 
2002) results appear contradictory, there are a number of studies showing that depending 
on which glutamate receptor subtype is stimulated, ACh release is either decreased or 
increased.  For example, ACh release in the striatum of awake, freely moving rat is 
increased by activation of NMDA receptors, whereas activation of non-NMDA receptors 
causes a decrease in ACh release (Anderson et al., 1994; Giovannini et al., 1995; Ikarashi 
et al., 1998).  Inhibition of NMDA receptors (Neigh-McCandless et al., 2002; Zmarowski 
et al., 2007) or AMPA and kainate receptors (Neigh-McCandless et al., 2002) in the 
nucleus accumbens of awake rat causes an increase in ACh release in the cortex.  In the 
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medial septum, NMDA receptors appear to be more important in mediating the increase 
in ACh release in the hippocampus than AMPA or kainate receptors (Moor et al., 1998).  
Stimulation of AMPA receptors in the basal forebrain of awake, freely moving rats 
(Fadel et al., 2001) and urethane-anesthetized rats (Fournier et al., 2004) causes an 
increase in ACh release in the cortex.  It is evident from these studies that depending on 
the brain region, activation of specific glutamate receptor subtypes causes either an 
increase or a decrease in ACh release.  
The mechanism(s) by which activation of different glutamate receptor subtypes 
cause either increased or reduced ACh release is unknown.  One possible explanation is 
that the synaptic location (e.g., GABAergic or glutamatergic neurons) of the specific 
glutamate receptor subtypes dictates whether ACh release is increased or decreased.  One 
can also speculate that the relative expression level of specific glutamate receptor 
subtypes determines whether glutamate increases or decreases ACh release.  One possible 
explanation why glutamate in the PnO did not increase ACh release is that there are more 
functional non-NMDA receptors in the PnO, and activation of these receptors overrides 
the effect of activating NMDA receptors, resulting in decreased ACh release.  
Role of glutamate receptor subtypes in modulating sleep and wakefulness 
Activation of specific glutamate receptor subtypes might produce different effects 
on the sleep-wake cycle.  Seminal studies demonstrated that kainate receptors in the PPT 
are key for generating REM sleep, whereas NMDA receptors in the PPT are key for 
generating wakefulness (Datta et al., 2001b; Datta, 2002; Datta et al., 2002).  Electrical 
stimulation of the LDT/PPT can cause either an increase in wakefulness (Steriade, 1993) 
or an increase in REM sleep (Thakkar et al., 1996).  Additionally, electrical stimulation 
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of the LDT/PPT causes an increase in ACh release in the pontine reticular formation 
(Lydic and Baghdoyan, 1993).  Depending on the concentration administered to the 
pontine reticular formation, cholinergic agonists can cause either an increase in REM 
sleep or wakefulness (Baghdoyan et al., 1989; Bourgin et al., 1995; Marks and Birabil, 
2001).  Whether activation of NMDA receptors in the PPT causes a further increase in 
ACh release compared to activation of kainate receptors in the PPT is not known.  
Evidence that glutamate interacts with GABA to decrease ACh release 
The observed inhibitory effect of glutamate in the PnO on ACh release is likely to 
involve GABAergic receptors.  One study demonstrated that the inhibitory effect of non-
NMDA receptors on ACh release in the striatum was reversed by the GABAA receptor 
antagonist bicuculline (Giovannini et al., 1995).  These findings encourage future studies 
to test the hypothesis that co-administration of bicuculline and glutamate to the PnO will 
block the glutamate-induced decrease in ACh release in the PnO.  Consistent with the 
notion that glutamate interacts with GABA to inhibit ACh release in the PnO is that 
bicuculline causes an increase in ACh release (Vazquez and Baghdoyan, 2004), 
demonstrating that GABAergic transmission in the PnO inhibits ACh release in the PnO.  
Although glutamate in the PnO might interact with GABA to inhibit ACh release, the 
potential involvement of glycine in the PnO should not be disregarded (Camacho-Arroyo 
and Tapia, 1992; Hasegawa et al., 2000).      
In addition to demonstrating that glutamate in the PnO modulates ACh release, 
the results from Chapter 3 might also provide insight into the synaptic mechanisms by 
which administration of hypocretin to the PnO increases both ACh release (Bernard et al., 
2003, 2006) and GABA levels in the PnO (Watson et al., 2008).  As previously 
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mentioned in the introduction, several studies show that hypocretin-1 and glutamate 
interact (Li et al., 2002; Alam and Mallick, 2008; Fadel and Frederick-Duus, 2008).  
However, it is unknown whether hypocretin-1 and glutamate interact in the PnO.  
However, one can speculate that hypocretin might interact with glutamate to increase 
both ACh release and GABA levels in the PnO.  Synaptic models for how hypocretin-1, 
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This Ph.D. thesis research investigated the mechanisms by which administration 
of hypocretin-1 to the PnO promotes wakefulness and also tested the effect of 
administration of glutamate to the PnO on ACh release.  The results are consistent with 
the interpretation that hypocretin-1 in the PnO promotes wakefulness by activating 
hypocretin receptors and GABAA receptors, and that glutamate in the PnO modulates 
ACh release.  These results are discussed below in the context of possible synaptic 
mechanisms by which hypocretin-1 promotes wakefulness.  Possible future studies and 
clinical implications are also discussed. 
The findings in Chapter 2 are the first to show that microinjection of hypocretin-1 
into rat PnO causes a concentration-dependent increase in wakefulness by increasing the 
duration of wakefulness episodes and by decreasing the number of wakefulness episodes 
(Fig. 2.3 A,D,G) (Brevig et al., 2010).  These results support a recent modeling study that 
predicts hypocretin-1 preferentially acts to consolidate wakefulness (Dinz Behn et al., 
2008).  Furthermore, the hypocretin-1-induced consolidation of wakefulness into longer 
episodes is consistent with the finding that narcoleptic patients (Taheri et al., 2002; 
Scammell, 2003) and  mice lacking hypocretin (Mochizuki et al., 2004; Zhang et al., 
2007) show fragmentation of sleep and wakefulness.   
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 Having demonstrated that administration of hypocretin-1 to the PnO causes a 
concentration-dependent increase in wakefulness (Fig 2.3A) (Brevig et al., 2010), 
additional experiments were designed to determine whether the increase in wakefulness 
is caused by activation of hypocretin receptors in the PnO. These studies used the hcrt-1 
antagonist SB-334867 to block the hypocretin-1-induced increase in wakefulness (Fig. 
2.6).  SB-334867 has a 50-fold higher affinity for hcrt-r1 than hcrt-r2, (Smart et al., 
2001), supporting the interpretation that hcrt-r1 mediates the wakefulness response.  
Whether endogenous hypocretin-1 in the PnO normally functions to promote wakefulness 
is unknown.  Future experiments could address this question by determining whether 
blocking hypocretin receptors causes a concentration-dependent decrease in wakefulness. 
Brain regions that regulate sleep and wakefulness differentially express hcrt-r1 
and hcrt-r2, and in some of these brain regions the expression level of hcrt-r1 and hcrt-r2 
also varies.  The relative importance of hypocretin receptor subtypes in regulating sleep 
and wakefulness is not well understood.  Systemic administration of SB-334867 
increased sleep (Smith et al., 2003) and resting duration (Duxon et al., 2001), indicating 
that hcrt-r1 activation is important in regulating sleep and wakefulness.  In contrast, 
subcutaneous administration of another hcrt-r1 antagonist, SB-408124, did not alter 
sleep-wake states (Dugovic et al., 2009).  Whether these differences are due to 
differences in the compounds and/or the routes of administration is unknown.  
Subcutaneous administration of a hcrt-r2 antagonist JNJ-10397049 caused a decrease in 
wakefulness and an increase in sleep (Dugovic et al., 2009).  Future experiments may 
determine the relative contribution of hypocretin receptor subtypes in different brain 
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regions in regulating sleep and wakefulness by using specific hypocretin receptor 
agonists and antagonists. 
Multiple lines of evidence demonstrate that hypocretins and GABA functionally 
interact.  Hypocretin-1 excites GABAergic neurons in the brainstem reticular formation 
(Li et al., 2002; Brown et al., 2008), substantia nigra (Korotkova et al., 2002), and the 
medial septum (Wu et al., 2002).  Inhibition of neurons in the PnO caused by hypocretin-
1 application is blocked by bicuculline (Nuñez et al., 2006), suggesting that the inhibition 
is mediated by GABAA receptors.  Further evidence supporting this interpretation is that 
hypocretin receptors are localized on GABAergic neurons in the PnO (Brischoux et al., 
2008).  Hypocretin and GABA also have been shown to interact in the lateral 
hypothalamus.  The increase in wakefulness caused by lateral hypothalamic 
administration of the GABAA receptor antagonist bicuculline correlates with increased 
activity of hypocretinergic neurons (Alam et al., 2005).  Hypocretin and GABA do not 
always interact as shown by a study in which administration of hypocretin-1 to the 
substantia innominata did not alter GABA levels (Fadel and Burk, 2009).  The results in 
Chapter 2 are the first to report that GABAergic transmission in the PnO is necessary for 
the hypocretin-1-induced increase in wakefulness (Fig 2.6).  Narcoleptic patients without 
disrupted nighttime sleep display higher GABA levels in the medial prefrontal cortex 
than narcoleptic patients with disrupted nighttime sleep (Kim et al., 2009), suggesting 
that GABA might act to reduce sleep disturbances.  Few studies have evaluated the 
functional importance of another class of GABA receptors, the metabotropic GABAB 
receptors, in relation to narcolepsy.  Selective deletion of GABAB receptors on 
hypocretinergic neurons in mice results in sleep fragmentation that is more severe than in 
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hypocretin knockout mice (Matsuki et al., 2009), suggesting a role of GABAB receptors 
in maintaining wakefulness.   
Treatments for narcolepsy target the symptoms and not the pathophysiology of 
the disease, hypocretin deficiency (Fujiki and Nishino, 2005).  An ideal treatment for 
narcolepsy would be to replace hypocretin similar to the way L-DOPA is used to treat 
Parkinson’s disease.  However, the therapeutic use of hypocretin-1 to treat narcolepsy is 
limited because the ability of peptides to penetrate the central nervous system is 
restricted.  Therefore, it is important to develop drugs that target the downstream 
effectors of hypocretin. Results from the Chapter 2 studies further our understanding of 
how hypocretin increases wakefulness and contribute to the rationale design of more 
selective drugs to treat narcolepsy. 
Although glutamate is a major neurotransmitter in the PnO (Lai et al., 1999), little 
is known about the effects of glutamate in this brain region on sleep and wakefulness.  A 
recent report suggests a causal relationship between glutamate levels in the PnO and 
wakefulness (Watson et al., 2008a).  One possible mechanism by which glutamate alters 
sleep-wake states is by modulating ACh release in the PnO.  The findings in Chapter 3 
are the first to report that administration of glutamate to the PnO decreases ACh release 
in the PnO (Fig. 3.1). Administration of the NMDA receptor antagonist, ketamine, also 
causes a decrease in ACh release in the PnO (Lydic and Baghdoyan, 2002). Results from 
Aim 3 studies support further investigation of the role of glutamate in modulating ACh 
release in the PnO.  Concentration-response studies would help determine whether 
glutamate could cause a biphasic, concentration-dependent change in ACh release.  
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Cataplexy is the sudden loss of muscle tone that is observed in both narcoleptic 
patients and in animal models of narcolepsy.  Administration of the muscarinic receptor 
agonist carbachol to the PnO produces cataplexy that is mediated by M2 receptors (Reid 
et al., 1994).  However, administration of the glutamate receptor agonists AMPA and 
kainate into the PnO does not produce cataplexy (Reid et al., 1994).  These results are in 
line with the Chapter 3 results showing that glutamate in the PnO inhibits ACh release in 
the PnO.   
 The mechanisms by which glutamate in the PnO decreases ACh release are 
unknown, but may involve activation of GABAergic neurons.  GABA inhibits the release 
of ACh in a number of brain regions (Moor et al., 1998; Materi and Semba, 2001), and 
blocking GABAA receptors enhances ACh release in the PnO (Vazquez and Baghdoyan, 
2004; Marks et al., 2008).  Administration of the GABAA receptor antagonist bicuculline 
reversed the inhibitory effect of glutamate on striatal ACh release (Giovannini et al., 
1995).  These findings encourage future studies that will test the hypothesis that co-
administration of bicuculline and glutamate to the PnO blocks the glutamate-induced 
decrease in ACh release in the PnO.   
 Results presented in Chapters 2 and 3 provide novel insight into possible synaptic 
mechanisms by which hypocretin-1 increases both GABA levels (Watson et al., 2008b) 
and ACh release (Bernard et al., 2003).  How can hypocretin-1 in the PnO increase both 
GABA levels and ACh release when evidence suggests that GABAergic transmission in 
the PnO inhibits ACh release (Vazquez and Baghdoyan, 2004; Marks et al., 2008)?  
Further adding to the conundrum are data demonstrating that GABA in the PnO 
suppresses REM sleep whereas ACh release in the PnO enhances REM sleep.  However, 
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administration of cholinomimetics at high concentrations to the PnO can cause an 
increase in wakefulness (Bourgin et al., 1995; Marks and Birabil, 2001).   
The simplest explanation for how hypocretin-1 increases ACh release is that 
hypocretin receptors may be located presynaptically on cholinergic terminals.  However, 
I propose three synaptic models that integrate the present Ph.D. thesis findings with 
previous functional and immunohistochemical studies.  These models each propose that 
hypocretin-1 increases ACh release in the PnO by interacting with both GABA and 
glutamate (Fig 4.1).  Although it is not known whether hypocretin-1 and glutamate 
interact in the PnO, several studies have shown that hypocretin-1 and glutamate interact 
in other brain regions (Kodama et al., 2002; Li et al., 2002; Alam and Mallick, 2008; 
Fadel and Frederick-Duus, 2008; Tose et al., 2009a, b).  In Model A, hypocretin release 
in the PnO simultaneously stimulates both GABA and glutamate release.  The released 
GABA then acts on postsynaptic GABA receptors on a GABAergic interneuron, which 
inhibits GABA release, resulting in increased ACh release. The released glutamate 
caused by hypocretin-1 in the PnO activates postsynaptic glutamate receptors on a 
GABAergic interneuron to increase GABA levels, resulting in decreased ACh release.  
Model A assumes that the increase in GABA levels caused by hypocretin-1 overrides the 
effect of increased glutamate release.  In Model B, hypocretin release in the PnO 
stimulates GABA release.  Activation of postsynaptic GABA receptors on a 
glutamatergic neuron results in disfacilitation of a separate GABAergic neuron and 
therefore, an increase in ACh release.  Similar to Model B, hypocretin-1 stimulates 
GABA release in Model C.  GABA activates postsynaptic GABA receptors on a 
GABAergic interneuron that synapses on presynaptic cholinergic terminals.  Inhibition of 
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the GABAergic interneuron will cause an increase in ACh release.  The PnO is composed 
of a heterogeneous population of neuronal types with many different synaptic 
connections.  The proposed models in Figure 4.1 are not the only possible synaptic 
connections by which hypocretin-1 can increase both GABA levels and ACh release.   
Uncovering the mechanisms mediating the hypocretin-induced increase in 
wakefulness will pave the way to other pharmaceutical targets that will benefit patients 
with sleep disorders, such as narcolepsy or insomnia.  Therefore, it is important to 
develop selective hypocretin receptor agonists and antagonists as well as learn more 
about hypocretin receptor signaling across states and brain regions. 
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Figure 4.1.  Three possible synaptic models in which hypocretin-1 in the PnO increases 
both ACh release and GABA levels.  The models are based on research described in this 
Ph.D. thesis and on results from previous studies.  The numbers shown on the models 
indicate citations.  1. Hypocretin neurons innervate the PnO (Peyron et al., 1998).  2. 
Hypocretin receptors localize on GABAergic neurons in the PnO (Brischoux et al., 
2008).  3.  Hypocretin increases GABA levels in the PnO (Watson et al., 2008b).  4.  Not 
all GABAergic neurons in the PnO contain hypocretin receptors (Brischoux et al., 2008).  
5. It is not known whether there are GABAA receptors on cholinergic neurons, however, 
the GABAA receptor antagonist, bicuculline causes an increase in ACh release in the PnO 
(Vazquez and Baghdoyan, 2004).  6. Cholinergic neurons in the LDT/PPT project to the 
PnO (Shiromani et al., 1988).  7. Hypocretin increases ACh release in the PnO (Bernard 
et al., 2003, 2006).  It is not known if hypocretin and glutamate (Glu) interact in the PnO.  
Therefore, each model shows either hypocretin in the PnO increasing (A), decreasing (B), 
or (C) having no effect on Glu levels.  The finding that glutamate in the PnO decreases 
ACh release (Chapter 3) supports the interpretation that glutamate receptors localize on 
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APPENDIX 
NEUROTRANSMITTERS AND NEUROMODULATORS  
REGULATING SLEEP AND WAKEFULNESS 
 
Synopsis 
Wakefulness, NREM sleep, and REM sleep are modulated by complex interactions 
between multiple neurotransmitters and neuromodulators acting in many different brain 
areas.  This chapter selectively highlights progress in understanding the role of selected 
neurotransmitters regulating states of sleep and wakefulness.  
1. Definitions 
EEG  electroencephalogram; the electrical activity of the cerebral cortex 
measured by placing electrodes on the skull.  The different stages of sleep are defined, in 
part, by characteristic pattern of cortical electrical activity 
GABA  gamma-aminobutyric acid; the major inhibitory neurotransmitter in the 
brain.  The binding of GABA to its receptor on the surface of a neuron reduces the 
probability that the neuron will discharge 
LDT/PTT laterodorsal and pedunculopontine tegmental nuclei; a brainstem nucleus 
located at the border between the midbrain and pons which contains cholinergic neurons 
that play an important role in the generation of REM sleep 
NREM  non-rapid eye movement; the majority of sleep time is spent in NREM 
sleep, which is divided into four stages.  Stages 1 and 2 are lighter states of sleep, 
whereas stages 3 and 4 are deeper and more resorative.  Stages 3 and 4 together are also 
 104
 
called slow wave sleep because the cortical electroencephalogram is characterized by 
slow frequency (0.5 to 4 Hz) waves.  Normal sleep is characterized by an orderly 
progression from Stages 1 to 4 and then back up to Stage 2, from which REM sleep is 
entered. 
pontine an adjective meaning of the pons; normally used to describe neurons that 
are located in the part of the brainstem called the pons 
Pontine reticular formation PRF; a group of brainstem neurons that forms the pontine 
component of the ascending reticular activating system 
2. Neurotransmitters Neuromodulators Regulating Sleep 
 Sleep neurobiology aims to elucidate the mechanisms by which states of sleep and 
wakefulness are generated by the brain.  Great progress in achieving this aim has been 
made since the discovery of rapid eye movement (REM) sleep in 1953 by Eugene 
Aserinsky and Nathanial Kleitman.  A mechanistic understanding is emerging from 
studies that have identified sleep related brain regions, neurotransmitters, and receptors.  
This review highlights some of the key neurotransmitters involved in the process of sleep 
cycle control, with an emphasis on sleep state dependent changes in neurotransmitter 
release.  Figure 1 shows the location of the neurons that synthesize these 
neurotransmitters, and schematizes some of their projection pathways relevant for sleep. 
 
2.1. Acetylcholine (ACh) was the first neurotransmitter discovered and is an 
important mediator of wakefulness, REM sleep, motor control, and the autonomic 
system.  The brain contains two major cholinergic projection systems, both of which play 
a role in generating states of sleep and wakefulness.  ACh-containing neurons in the basal 
 105
 
forebrain project to the neocortex and hippocampus, where acetylcholine functions to 
activate the electroencephalogram (EEG), mediate focused attention, and consolidate 
memories.  Cholinergic neurons in the basal forebrain fire fastest during wakefulness and 
REM sleep, and discharge more slowly during non-REM (NREM) sleep.  This discharge 
pattern of basal forebrain cholinergic neurons is consistent with the acetylcholine release 
pattern measured in the cerebral cortex (Table A.1).  The degeneration of basal forebrain 
cholinergic neurons that occurs in Alzheimer’s disease contributes to memory loss, 
daytime sleepiness, and disrupted nighttime sleep in these patients.  A second group of 
acetylcholine containing neurons is found in the laterodorsal and pedunculopontine 
tegmental nuclei (LDT/PPT) of the brain stem.  LDT/PPT neurons project up to the 
thalamus, hypothalamus, and basal forebrain, as well as down to numerous brain stem 
nuclei, including the pontine reticular formation.  One group of cholinergic LDT/PPT 
neurons discharges selectively during REM sleep, consistent with the finding that 
acetylcholine release in the pontine reticular formation is greatest during REM sleep 
(Table A.1).  A second group of LDT/PPT neurons fires fastest during wakefulness and 
REM sleep, consistent with the pattern of relatively high ACh release in the thalamus 
during wakefulness and REM sleep and relatively low thalamic ACh release during 
NREM sleep (Table A.1). 
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Table A.1.  State Dependent Changes in Acetylcholine Release Vary According to Brain 
Region  
Brain Region Acetylcholine Release Species Reference 
cerebral cortex Wake = REM > NREM cat Science 192:161-162, 1971 
DTF REM  > Wake = NREM cat Neurosci Letts 114: 277-282, 1990 
caudate nucleus Wake = REM > NREM cat ibid 
NMC Wake = REM > NREM cat Brain Res 580: 348-350, 1992 
NPM REM > Wake = NREM cat ibid 
thalamus Wake = REM > NREM rat J Neurosci 14: 5236-5242, 1994 
cerebral cortex Wake > REM > NREM cat Brain Res 671:329-332, 1995 
hippocampus REM > Wake > NREM cat ibid 
PRF REM > Wake = NREM cat J Neurosci 17: 774-785, 1997 
basal forebrain REM > Wake > NREM cat Am J Physiol Regul Integr Comp 
Physiol 280:598-601, 2001 
 
Table A.1 abbreviations: DTF (dorsal tegmental field, part of the pontine reticular formation), NPM 
(nucleus paramedianus, part of the medullary reticular formation), NMC (nucleus magnocellularis, part of 
the medullary reticular formation), PRF (pontine reticular formation) 
 
 Although acetylcholine release during sleep and wakefulness differs according to 
brain region, one consistent finding is that in all of the brain regions analyzed, 
acetylcholine levels are greatest when the EEG is activated, such as during REM sleep 
and wakefulness.  During NREM sleep when the EEG is deactivated, acetylcholine 
release is at its lowest (Table A.1). 
 Acetylcholine exerts its effects by activating two major classes of receptors called 
nicotinic and muscarinic.  Nicotinic receptors are ligand-gated ion channels and exist as 
17 subtypes.  Activating nicotinic receptors in the thalamus contributes to cortical 
activation by suppressing slow wave activity characteristic of NREM sleep.  There are 
five muscarinic receptor subtypes.  M1, M3, and M5 receptors are coupled to excitatory 
G proteins whereas M2 and M4 receptors are coupled to inhibitory G proteins. 
Acetylcholinesterase hydrolyzes acetylcholine to choline and acetic acid.  Nerve gases 
inhibit acetylcholinesterase to increase acetylcholine levels, which leads to muscle 
paralysis and death.  
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 Additional insights concerning the endogenous neurotransmitter regulating sleep 
have come from administering drugs into specific brain regions of experimental animals 
while recording sleep and wakefulness.  Delivering drugs into the brain is possible, in 
part, because the brain has no pain receptors.  Thus, sleep can be studied humanely in 
animals following drug administration into specific brain regions.  These types of studies 
provide insights into the sleep related functions of specific brain regions and receptor 
subtypes localized within those brain regions.  For example, pontine reticular formation 
microinjection of drugs that mimic the effects of acetylcholine causes an increase in 
REM sleep.  These data fit well with the observation that acetylcholine release in the 
pontine reticular formation is increased during REM sleep (Table A.1).  In the pontine 
reticular formation, drugs that are effective for increasing REM sleep includ those that 
inhibit the breakdown of endogenous acetylcholine and drugs that activate M2 
muscarinic cholinergic receptors.  Studies in humans have shown that administering low 
doses of acetylcholinesterase inhibitors also causes an increase in REM sleep.  Taken 
together, these data support the interpretation that the cholinergic transmission in the 
pontine reticular formation contributes to the generation of REM sleep. 
 
2.2. Serotonin is a monoamine neurotransmitter that contributes to the regulation of 
appetite, emotion, vascular smooth muscle tone, and wakefulness.  Serotonin is 
synthesized by the raphé nuclei of the brain stem and these nuclei project widely to the 
rest of the brain.  The dorsal raphé nucleus has been most thoroughly studied with respect 
to sleep and wakefulness.  The firing rate of serotonergic dorsal raphé neurons is fastest 
during wakefulness, slower during NREM sleep, and slowest during REM sleep, 
 108
 
suggesting that serotonin promotes wakefulness and is inhibitory to REM sleep.  
Fourteen serotonin receptor subtypes have been identified, and are expressed throughout 
the brain and periphery.  Clinically, serotonin receptor agonists are used for treating 
migraine, headache, and preventing nausea.  Serotonin reuptake inhibitors, which block 
uptake of serotonin from the synapse to increase serotonin levels, are used to treat 
depression.  A consistent finding across most brain regions studied to date is that 
serotonin levels are highest during wakefulness, lower during NREM sleep, and lowest 
during REM sleep (Table A.2).  These measures of serotonin release support the 
interpretation that high serotonin levels are important for wakefulness, and that a 




Table A.2.  Serotonin Release is Greater during Wakefulness than during Sleep, 
Independent of Brain Region 
Brain Region Serotonin Release Species Reference 
PRF Wake > NREM > REM cat Neurosci Res 18:157-70, 1993 
dorsal raphé Wake > NREM > REM rat Neuroscience 83:807-814, 1998 
frontal cortex Wake > NREM > REM rat ibid
dorsal raphé Wake > NREM > REM cat Brain Res 648: 306-312, 1994 
PPT Wake > NREM > REM cat Sleep Res Online 2:21-27, 1999 
amygdala Wake > NREM = REM cat Brain Res 860:181-189, 2000 
locus coeruleus Wake > NREM > REM cat ibid 
hippocampus Wake > NREM > REM rat Eur J Neurosci 17:1896-1906, 2003 
Table A.2 abbreviations: PRF (pontine reticular formation) PPT (pedunculopontine tegmental nucleus) 
 
2.3. Norepinephrine promotes wakefulness and is an important mediator of 
autonomic function and muscle tone.  Neurons that synthesize norepinephrine are 
concentrated in the brain stem nucleus called the locus coeruleus.  These neurons project 
rostrally to the forebrain and cerebral cortex, as well as caudally to the brain stem and 
spinal cord.  Similar to the serotonergic neurons described above, noradrenergic neurons 
fire at their fastest rates during wakefulness, slow their discharge during NREM sleep, 
and cease firing during REM sleep.  This “Wake-on/REM-off ” discharge pattern is 
unique to monoaminergic neurons and is consistent with the wakefulness promoting role 
of norepinephrine.  As a result of the unique state dependent discharge pattern, 
norepinephrine release is higher during wakefulness than during sleep in all brain regions 




Table A.3.  Norepinephrine Release is Greater during Wakefulness than during 
Sleep, Independent of Brain Region 
Brain Region Norepinephrine Release Species Reference 
locus coeruleus Wake > NREM > REM cat Brain Res 860:181-189, 2000 
amygdala Wake > NREM > REM cat, rat Brain Res 860:181-189, 2000; J 
Korean Med Sci 17:395-399, 2002 
nucleus accumbens Wake > NREM = REM rat J Neurosci Res 81:891-899, 2005 
prefrontal cortex Wake > NREM = REM rat ibid 
 
 Clinically, norepinephrine has many uses including the treatment of shock 
because it acts as a vasoconstrictor.  Norepinephrine binds to and activates α and β 
receptors.  There are two α noradrenergic receptors, α1 and α2.  The α2 receptors 
function as autoreceptors to regulate the release of norepinephrine.  The α2 receptor 
agonist dexmedetomidine is used frequently in the intensive care unit setting to provide 
sedation.  Xylazine is an α2 receptor agonist used clinically in veterinary practice for 
sedation.  Preclinical studies have shown that dexmedetomidine inhibits the firing of 
wakefulness promoting locus coeruleus neurons.  
 
2.4. Histamine is a monoamine synthesized in the tuberomammillary nucleus of the 
posterior hypothalamus.  These neurons send projections throughout the brain, including 
the sleep-promoting anterior hypothalamus, the arousal promoting LDT/PPT, and the 
neocortex.  Similar to the other monoamines serotonin and norepinephrine, histaminergic 
neurons fire with a wake-on/REM-off discharge pattern and function to promote 
wakefulness.  Histamine also modulates the immune system and gastric acid secretion.  
Histamine is synthesized by the enzyme histadine decarboxylase.  Knock out mice 
lacking the gene responsible for histamine synthesis show slow frequencies in the EEG 
during wakefulness, suggesting that they are less alert than control mice.  In addition, 
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mice that cannot synthesize histamine do not show the normal increased wakefulness in 
response to a novel environment.   
There are three known subtypes of histamine receptors, H1-H3, which are 
coupled to G proteins.  H1 and H2 receptor antagonists are used clinically to block 
allergic responses and gastric acid secretions, respectively.  First generation 
antihistamines cause drowsiness, and H1 receptor knockout mice show a decreased 
waking response to the arousal promoting peptide hypocretin (orexin).  Less is known 
about H3 receptor subtype function except that it is an autoreceptor and modulates the 
release of histamine.  Histamine release has only been studied in a few brain regions 
during sleep and is highest during wakefulness, similar to serotonin and norepinephrine 
(Table A.4). 
Table A.4.  Histamine Release is Greater during Wakefulness than during Sleep 
Brain Region Histamine Release Species Reference 
preoptic 
hypothalamic area 
Wake > REM > NREM cat Neuroscience 114:663-670, 2002 
prefrontal cortex Wake > Sleep rat Neurosci Res 49:417-420, 2004 
 
 Inhibiting tuberomammillary neurons with the GABAA receptor agonist muscimol 
causes a decrease in wakefulness and an increase in sleep, consistent with a wakefulness 
promoting role for histamine and a sleep-promoting role for GABA.  Microinjection of an 
H1 receptor agonist into the LDT also causes an increase in wakefulness, as does 
administering histamine into the basal forebrain.  Consistent with these finding are data 
showing that increasing histamine levels in the tuberomammillary nucleus by blocking 
the enzymatic degradation of histamine also increases wakefulness and decreases both 
NREM sleep and REM sleep.  In general, the wakefulness promoting effects of histamine 
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are mediated by the H1 receptor, whereas increases in sleep are produced by drugs that 
activate H2 or H3 receptors. 
 
2.5. Dopamine is the precursor of norepinephrine and mediates mood, motor activity, 
addiction, and the secretion of prolactin.  The D1 family (D1, D5) of dopamine receptors 
is coupled to stimulatory G proteins to activate adenlycyclase.  The D2 family (D2, D3, 
D4) of dopamine receptors is coupled to inhibitory G proteins that inhibit adenylcyclase.  
Similar to norepinehprine, dopamine is used clinically to treat shock.  Dopamine neurons 
of the substantia nigra selectively degenerate in Parkinson’s Disease, which is 
characterized by excessive daytime sleepiness and disrupted nighttime sleep.  Dopamine 
receptor agonists are widely used to treat Parkinson’s disease.  The firing rates of 
dopaminergic neurons in the ventral tegmental area and substantia pars compacta do not 
vary across sleep-wake states.  However, dopamine levels do vary across sleep-wake 
states in the frontal cortex, nucleus accumbens, and spinal cord (Table A.5).  The locus 
coeruleus appears to not be a target region for dopaminergic regulation of arousal state as 
dopamine levels do not show state specific changes. 
Table A.5.  State Dependent Changes in Dopamine Release Vary According to Brain 
Region 
Brain Region Dopamine Release Species Reference 
locus coeruleus Wake = NREM = REM cat Brain Res 860:181-189, 2000
frontal cortex Wake > NREM = REM rat J Neurosci Res 81:891-899, 2005
nucleus accumbens Wake = REM > NREM rat ibid 
spinal cord Wake = NREM > REM cat J Neurophysiol 100:598-608, 2008 
 
2.6. Hypocretins (also known as orexins) are neuropeptides discovered by separate 
groups in 1998 and play diverse roles in physiology by regulating arousal, feeding, 
nociception, energy homeostasis, neuroendocrine and cardiovascular functions.  The two 
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subtypes of hypocretins, hypocretin-1 (orexin A) and hypocretin-2 (orexin B) are 
synthesized in the lateral, posterior, and perfornical hypothalamus and project widely 
throughout the brain.  There are two receptor subtypes, hypocretin receptor-1 and 
hypocretin receptor-2.  Hypocretin receptor-2 binds both peptides equally, whereas 
hypocretin receptor-1 is selective for hypocretin-1.  Hypocretin deficiency underlies the 
sleep disorder narcolepsy, which is characterized by excessive daytime sleepiness and 
disrupted nighttime sleep, and can be accompanied by cataplexy, or the sudden loss of 
muscle tone. 
 One normal, physiological role of the hypocretins is the promotion of 
wakefulness.  Hypocretin levels are greater in the hypothalamus and the basal forebrain 
during wakefulness and REM sleep (when the EEG is activated) when compared to 
NREM sleep (Table A.6).  These data fit nicely with the increase in firing rate of basal 
forebrain neurons observed during wakefulness and the increase in activity seen from 
PET imaging in the basal forebrain.  Hypocretinergic neurons in the lateral hypothalamic 
area also increase firing rate during wakefulness.  Interestingly, hypocretin levels in locus 
coeruleus (wake promoting region) do not vary across sleep-wake states even though this 
is where the most hypocretin-1 receptors are located.  Hypocretin levels are greater 
during wakefulness than during sleep in the lateral hypothalamus and medial thalamus 
(Table A.6). 
Table A.6.  Hypocretin Release is Lowest during NREM Sleep 
Brain Region Hypocretin/Orexin Levels Species Reference 
lateral 
hypothalamus 
Wake > Sleep rat Eur J Neurosci 14:1075-1081, 2001 
hypothalamus  Wake = REM > NREM cat J Neurosci 22:5282-5286, 2002 
basal forebrain Wake = REM > NREM cat ibid 




Microdialysis studies suggest a causal relationship between neuromodulator levels 
and states of wakefulness, NREM sleep, and REM sleep.  Pharmacological approaches 
further describe the sleep-related roles of these sleep modulators in different brain 
regions.  Understanding the interactions between sleep modulatory neurochemical 
systems in different brain regions as well as deciphering the effects of specific 
neurotransmitter receptor subtype on sleep-wake states will pave the way for better 
pharmacological therapeutics for disorders of sleep and mental health. 
 
2.7. GABA is the major inhibitory neurotransmitter in the brain and is synthesized 
from glutamate.  Unlike the neurotransmitters discussed above, GABA is released from 
glial cells as well as from neurons.  These glial cells, or astrocytes, are in close proximity 
to synapses and modulate synaptic transmission.  Furthermore, GABA transporters reside 
on both neurons and astrocytes, so GABA is taken up into astrocytes. 
GABA binds to three types of receptors, GABAA, GABAB, and GABAC.  
GABAA and GABAC receptors are ligand-gated ion channels and GABAB is a G protein-
coupled receptor.  The GABAA receptor has binding sites for a variety of molecules that 
produce sedation, sleep, or general anesthesia.  Benzodiazepines also act via the GABAA  
receptor to reduce anxiety.  Almost all brain regions contain GABAergic interneurons.  
The basal forebrain also contains GABAergic projection neurons, which provide input to 
the cerebral cortex.  GABA levels in the cortex during sleep and wakefulness have not 
been measured.  GABAergic neurons in the anterior hypothalamus send projections to the 
wakefulness promoting monoaminergic neurons in the posterior hypothalamus, locus 
coeruleus, and dorsal raphé, as well as the cholinergic LDT/PPT neurons.  GABA levels 
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in the dorsal raphé, locus coeruleus, and posterior hypothalamus are higher during sleep 
than during wakefulness (Table A.7).  GABA levels in the LDT/PPT have not been 
measured during sleep and wakefulness, but GABAergic interneurons in the LDT/PPT 
are active during REM sleep.  The GABAA receptor agonist muscimol causes sleep when 
microinjected directly into the posterior hypothalamus, but causes wakefulness when 
delivered directly into the anterior hypothalamus.  These findings are consistent with the 
interpretation that GABA in these brain areas contributes to sleep generation by 
inhibiting wakefulness promoting neurons.  
Table A.7.  State Dependent Changes in GABA Levels 
Brain Region GABA Levels Species Reference 
dorsal raphe REM > Wake = NREM cat Am J Physiol 273: R451-R455, 
1997 
locus coeruleus  REM > NREM > Wake cat Neuroscience 78: 795-801, 1997 
posterior 
hypothalamus 
NREM > Wake = REM cat Am J Physiol Regul Comp Physiol 
271:1707-1712, 1996  
spinal cord REM > Wake = NREM cat J Neurophysiol 100:598-608, 2008
 
 GABA levels in the pontine reticular formation are greater during wakefulness 
than during NREM sleep, REM sleep, or general anesthesia.  These data indicate that 
GABA in the pontine reticular formation contributes to the generation of wakefulness.  A 
wakefulness promoting role for GABA is also supported by data showing that 
wakefulness is either increased or decreased by drugs that either increase or decrease, 
respectively, pontine reticular formation GABAergic transmission.  GABA and 
acetylcholine interact in the pontine reticular formation to regulate REM sleep.  
Activation of GABAA receptors in the pontine reticular formation decreases REM sleep, 
in part, by decreasing acetylcholine release.  Similarly, blocking GABAA receptors in the 
pontine reticular formation increases acetylcholine release and increases REM sleep.   In 
summary, GABAergic inhibition either inhibits or promotes wakefulness, depending 
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upon the brain region.  In brain regions that promote wakefulness, GABAergic inhibition 
functions to increase sleep.  In brain regions that promote sleep, GABAergic inhibition 
contributes to an increase in wakefulness. 
 
2.8. Glutamate is the major excitatory neurotransmitter in the brain and is the 
precursor to GABA.  Similar to GABA, glutamate is synthesized and released from 
neurons and glial cells.  Glutamate exhibits its actions by activating ionotropic NMDA, 
AMPA, or kainate receptors and metabotropic glutamatergic receptors.  Little is known 
about the role of glutamate in sleep cycle control.  Glutamate is excitatory, and in most 
brain areas, glutamate levels are highest during wakefulness or REM sleep, which are 
both activated brain states (Table A.8).   
Table A.8.  Glutamate Levels Vary Across the Sleep Wakefulness Cycle in a Brain 
Region Specific Manner 
Brain Region Glutamate Levels Species Reference 
NMC  REM > NREM = Wake cat Brain Res 780:178-181,1998 
NPM Wake= NREM = REM cat ibid 
NAcc  Wake > NREM = REM rat J Neurosci Res 81:891-899, 2005 
prefrontal cortex Wake = NREM = REM rat ibid 
oFC REM > Wake > NREM rat Arch Med Res 38:52-55, 2007 
spinal cord REM > NREM = Wake cat J Neurophysiol 100:598-608, 2008 
PH/TMN Wake = REM > NREM rat Am J Physiol Regul Integr Comp 
Physiol 295:R2041-R2049, 2008 
Table A.8 abbreviations:  NPM (nucleus paramedianus), NMC (nucleus magnocellularis), NAcc (nucleus 
accumbens, oFC (orbital frontal cortex), TMN (tuberomamillary nucleus) 
 
The results from studies that have microinjected glutamatergic drugs into the 
brain and quantified the effects on sleep and wakefulness have shown that glutamate 
promotes either wakefulness or REM sleep, depending on the brain region where 
glutamate is administered.  Glutamate at lower doses delivered directly into the PPT 
causes REM sleep and at higher doses causes wakefulness.  The increase in REM sleep is 
mediated by kainate receptors and the increase in wakefulness results from activating 
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NMDA receptors.  Furthermore, activating the metabotropic glutamate subtype II 
receptor decreases wakefulness and increases NREM sleep.  These data demonstrate that 
endogenous glutamate is an important regulator of arousal and suggest that in the PPT, 
activation of kainate and NMDA receptors is important for inducing sleep whereas 
activating metabotropic subtype II receptors is important for inducing wakefulness.  
Administration of glutamate to the dorsal raphé or basal forebrain increases wakefulness 
and decreases sleep. 
Ketamine is an NMDA receptor agonist and is used clinically to produce a state of 
dissociative anesthesia.  The term dissociative arose from the finding that when ketamine 
is used for surgical procedures, sensory information reaches the cortex but is not 
accurately perceived as painful, thus causing a dissociation between objective and 
subjective experience.  When given intravenously or directly into the pontine reticular 
formation, ketamine suppresses REM sleep and decreases the release of the REM sleep 
promoting transmitter acetylcholine. 
 
2.9. Adenosine is a purine nucleoside that is derived from the breakdown of ATP, and 
adenosine has many physiological functions.  The function of adenosine most relevant for 
this volume is as an endogenous promoter of sleep.  There are four adenosine receptor 
subtypes, A1, A2a, A2b and A3, which are G-protein-coupled receptors.  A1 and A3 
receptors inhibit adenyl cyclase activity whereas A2a and A2b receptors activate adenyl 
cyclase.  One of the most widely used legal drugs in the world is caffeine, which 
promotes wakefulness and increases alertness by blocking adenosine receptors.  
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Adenosine levels in the brain increase during wakefulness and decrease during sleep 
(Table A.9).   
Table A.9.  Adenosine Levels Increase during Wakefulness and Decrease during 
Sleep 
Brain Region Adenosine Levels Species Reference 
basal forebrain Wake > NREM = REM cat Neuroscience 99:507-517, 2000 
cortex Wake > NREM = REM cat ibid 
thalamus Wake > NREM = REM cat ibid 
preoptic area Wake > NREM = REM cat ibid 
dorsal raphé  Wake = NREM = REM cat ibid 
PPT Wake = NREM = REM cat ibid 
Table A.9 abbreviations: PPT (pedunculopontine tegmental nucleus) 
Adenosine levels in different brain regions have been quantified during sleep deprivation 
and subsequent recovery sleep.  These studies show that changes in adenosine levels 
during sleep deprivation and recovery sleep were different depending on the brain region 
analyzed.  For example, adenosine levels in the cortex and basal forebrain accumulate 
during prolonged wakefulness and fall during recovery sleep.  In contrast, adenosine 
levels do not increase in the dorsal raphé or pedunculopontine tegmental nucleus during 
sleep deprivation.  Furthermore, adenosine acting on A1 receptors inhibits wakefulness 
promoting neurons in the basal forebrain.  Adenosine also inhibits wakefulness 
promoting histaminergic and hypocretinergic neurons in the posterior and lateral 
hypothalamus, and increases the activity of anterior hypothalamic GABAergic neurons 
that promote sleep.  
 Pharmacological approaches have provided novel evidence that adenosine is sleep 
promoting.  Adenosine A1 receptor antagonists delivered directly into the pontine 
reticular formation or the prefrontal cortex shorten recovery time from general anesthesia, 
whereas A1 receptor agonists increase anesthesia recovery time.  Administering 
adenosine into the lateral dorsal tegmental nucleus decreases wakefulness and increases 
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sleep.  Adenosine A1 receptor activation in the pontine reticular formation increases 
REM sleep and decreases wakefulness.  Microinjection of A2a agonist into the pontine 
reticular formation increases acetylcholine release and increases REM sleep.  Taken 
together, current data demonstrate that although adenosine levels are highest during 
wakefulness (Table A.9), adenosine is a sleep promoting agent. 
 
3. Concluding Remarks 
Sleep is important for many physiological functions, including the immune 
system, cognition, learning and memory, and mental health.  As of 2006, over 70 million 
Americans suffer from sleep related disorders, costing an estimated 15.9 billion dollars 
(http://www.sleepmed.md/page/1896).  The elderly population is increasing, and the 
incidence of sleep disorders increases with aging.  Understanding how sleep is regulated 
by neurotransmitters and neuromodulators, and discerning how these transmitter and 
modulator system interact will improve the medications prescribed for sleep disorders.  In 
2008 a study demonstrated that the inverse histamine-3 receptor agonist tiprolisant 
reduces excessive daytime sleepiness in narcoleptic patients and in hypocretin deficient 
mice.  Modafinil is another drug used to reduce excessive daytime sleepiness, and 
although the mechanism of action is not well understood modafinil acts through multiple 
neurotransmitter systems.  Olanzapine is an atypical antipsychotic that improves sleep in 
schizophrenics and acts at several neurotransmitter receptors.  Future studies will need to 
focus more on elucidating interactions between multiple neurotransmitter systems and on 







Figure A.1.  Localization of the major neuronal groups and pathways regulating sleep 
and wakefulness on a drawing of the human brain.  A shows the major sleep-wake related 
neurons and their neurotransmitters.  B indicates cholinergic projections from the basal 
forebrain and the brainstem.  C schematizes the monoaminergic and hypocretinergic 
wakefulness promoting neurons and their projections.  D draws the projections from 
GABAergic neurons in the basal forebrain and preoptic area.  Abbreviations: ACh, 
acetylcholine; BF, basal forebrain; DR, dorsal raphe nucleus; DA, dopamine; Gal, 
galanin; LC, locus coeruleus; LDT-PPT, laterodorsal and pedunculopontine tegmental 
nucleus; NA, noradrenaline; PHA, posterior hypothalamic area; SC, spinal cord; 5-HT, 
serotonin; Th, thalamus, vlPAG, ventrolateral periaqueductal gray; VLPO, ventrolateral 
preoptic area.  From:  Vanini G, Baghdoyan HA, and Lydic R.  Relevance of sleep 
neurobiology for cognitive neuroscience and anesthesia.  In:  Awareness and 
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During the three years I spent in Dr. Jorge Iñiguez-Lluhí’s laboratory as a 
graduate student, my research focused on transcriptional regulation by the Small 
Ubiquitin-like Modifier (SUMO) family of proteins.  One of my first projects in the lab 
was to determine whether the Krüppel-type zinc finger binding protein ZBP-89 was 
SUMO-modified in vitro.  The published manuscript shown below includes the results 





SUMOYLATION-DEPENDENT CONTROL OF HOMOTYPIC AND 
HETEROTYPIC SYNERGY BY THE KRUPPEL-TYPE ZINC FINGER 
PROTEIN ZBP-89 
 




 The Krüppel-like transcription factor ZBP-89 is a sequence-specific regulator that 
plays key roles in cellular growth and differentiation, especially in endodermal and germ 
cell lineages.  ZBP-89 shares with other members of the Sp-like family an overlapping 
sequence specificity for GC rich sequences in the regulatory regions of multiple genes. 
Defining the mechanisms that govern the intrinsic function of ZBP-89 as well as its 
competitive and non-competitive functional interactions with other regulators is central to 
understand how ZBP-89 exerts its biological functions.  We now describe that post-
translational modification of ZBP-89 by multiple SUMO isoforms occurs at two 
conserved synergy control motifs flanking the DNA binding domain.  Functionally, 
SUMOylation does not directly alter the ability of ZBP-89 to compete with other Sp-like 
factors from individual sites.  At promoters bearing multiple response elements however, 
this modification inhibits the functional cooperation between ZBP-89 and Sp1.  Analysis 
of the properties of ZBP-89 in cellular contexts devoid of competing factors indicates that 
although on its own it behaves as a modest activator, it potently synergizes with 
heterologous activators such as the glucocorticoid receptor. Notably, we find that when 
conjugated to ZBP-89, SUMO exerts a strong inhibitory effect on such synergistic 
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interactions through a critical conserved functional surface.  By regulating higher-order 
functional interactions, SUMOylation provides a reversible post-translational mechanism 






Eukaryotic ZBP-89 (also known as BERF-1, BFCOL1 or ZNF148) is a widely 
expressed Krüppel-type transcription factor that harbors an N-terminal cluster of four 
(three canonical C2H2 and a variant C2H2) zinc-finger motifs.  In vivo experiments 
indicate that ZBP-89 plays important roles in the generation and maintenance of specific 
cell lineages since haploinsufficiency causes infertility in mice due to apoptosis of germ 
cells (Takeuchi et al., 2003) whereas knockdown of ZBP-89 in zebrafish disrupts early 
steps in hematopoiesis (Li et al., 2006).  ZBP-89 also appears to play important roles in 
the gastrointestinal tract since mice exclusively expressing a splice variant lacking the 
first 127 residues display increased sensitivity to colitis (Law et al., 2006b), whereas 
intestinal overexpression of ZBP-89 activates apoptosis and mitigates neoplasia burden in 
ApcMin/+ mice (Law et al., 2006a).  Functionally, ZBP-89 has been most often linked to 
transcriptional inhibition of genes such as those for gastrin, vimentin or ornithine 
decarboxylase (ODC) (Merchant et al., 1996; Law et al., 1998a; Law et al., 1998b; 
Wieczorek et al., 2000; Park et al., 2003; Boopathi et al., 2004). ZBP-89 shares with Sp1 
and other Sp-like factors the ability to recognize GC-rich sequences in target genes. This 
overlapping DNA recognition has led to a competitive model of inhibition where ZBP-89 
represses gene transcription by displacing proteins such as Sp1 or Sp3 (Merchant et al., 
1996; Cheng et al., 2000).  Thus, an analysis of the proximal ODC gene promoter 
revealed that Sp1 and ZBP-89 bind to GC elements in a mutually exclusive manner (Law 
et al., 1998b).  In other cases, ZBP-89 appears to inhibit by binding to DNA 
independently of Sp1 (Zhang et al., 2003). In addition to its role in transcriptional 
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inhibition, ZBP-89 has been implicated as a modest positive regulator of a set of genes 
including p21, lymphocyte-specific protein-tyrosine kinase (lck) and stromelysin (Ye et 
al., 1999; Yamada et al., 2001; Malo et al., 2005). In the case of the p21Waf1 promoter, 
recruitment of the coactivator p300 appears to contribute to activation of this gene (Bai 
and Merchant, 2000). The overlap in DNA binding specificity with widely expressed Sp-
like factors however, makes the mechanistic analysis of ZBP-89 function particularly 
challenging.  Broad dissection of ZBP-89 suggests that distinct regions are involved in 
negative and positive regulation with repressive and transactivating functions in the N-
terminal and C terminal regions, respectively (Hasegawa et al., 1997; Passantino et al., 
1998).  How these still poorly defined functions are selectively employed in different 
contexts and how ZBP-89 engages in competitive and non-competitive functional 
interactions with other factors remain poorly understood.  
An emerging mechanism to regulate higher order interactions among transcription 
factors involves the function of Synergy Control or SC motifs (Iñiguez-Lluhí and Pearce, 
2000).  These short regulatory sequences, which we first identified in the glucocorticoid 
receptor (Iñiguez-Lluhí and Pearce, 2000); are present in multiple factors across a wide 
range of families.  SC motifs are distinct from transcriptional activation functions and 
often map to negative regulatory regions. Functionally, SC motifs limit the synergistic 
transcriptional output from complexes assembled at multiple response elements without 
altering the activity of a regulator from a single site (Iñiguez-Lluhí and Pearce, 2000; 
Subramanian et al., 2003; Komatsu et al., 2004).  Mechanistically, we and others have 
demonstrated that SC motifs operate in an autonomous manner by serving as sites for 
reversible post-translational modification by members of the Small Ubiquitin-like 
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Modifier (SUMO) family of proteins (Poukka et al., 2000; Holmstrom et al., 2003; 
Subramanian et al., 2003; Komatsu et al., 2004).   
The mammalian SUMO family consists of four genes designated SUMO1-4.  
SUMO2 and 3 are closely related whereas SUMO1 shares ~ 48% identity to either 
SUMO2 or 3 (Saitoh and Hinchey, 2000; Su and Li, 2002).  A more recently identified 
gene encodes a fourth isoform very similar to SUMO2/3 (Bohren et al., 2004).  SUMO 
proteins are structurally related to ubiquitin, and the analogous SUMO modification 
pathway is carried out by a distinct, SUMO-specific set of enzymes.  Following 
translation, processing by SUMO proteases removes C-terminal residues in SUMO to 
expose a conserved di-glycine motif (Johnson, 2004).  Notably, SUMO4 harbors a Pro 
residue at position 90, which prevents initial processing by known SUMO protease 
enzymes and subsequent conjugation (Owerbach et al., 2005). Whether this member 
functions through non-covalent interactions only remains to be determined.  After this 
initial cleavage, SUMO is then activated in ATP-dependent manner by the heterodimeric 
E1-activating enzyme SAE1/SAE2. The thioester-linked SUMO is then transferred to the 
SUMO specific E2-conjugating enzyme Ubc9 which in turn, recognizes specific 
substrates and catalyzes the formation of an isopeptide bond between SUMO and the 
target lysine. This step is facilitated by SUMO E3 ligases such as RanBP2 and members 
of the protein inhibitor of activated STAT (PIAS) family (Sachdev et al., 2001; Pichler et 
al., 2002; Chun et al., 2003).  Finally, SUMO conjugation is reversed through the 
isopeptide activity of SUMO specific proteases (Yeh et al., 2000).  Recent functional and 
structural analysis by our group (Chupreta et al., 2005) indicates that once conjugated, 
individual SUMO isoforms mediate their distinct effects through a conserved surface that 
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interacts with Val/Leu rich motifs in target proteins (Song et al., 2004; Reverter and 
Lima, 2005; Lin et al., 2006; Rosendorff et al., 2006).  The nature of the SUMO-
interacting proteins responsible for SUMO-dependent transcriptional inhibition remains 
poorly defined but may include HDACS and DAXX (Yang and Sharrocks, 2004; Lin et 
al., 2006) as well as other proteins (Rosendorff et al., 2006). Although the role of SC 
motifs and SUMOylation in the regulation of the synergistic effect of potent 
transcriptional regulators such as the glucocorticoid receptor is becoming better 
understood (Holmstrom et al., 2003; Chupreta et al., 2005), the impact of this regulatory 
mechanism on factors that are generally viewed as dominant-negative or “decoy” 
relatives of other factors remains largely unexplored.  
 In the present study, we identify and characterize two synergy control motifs that 
flank the zinc-finger cluster DNA-binding domain of ZBP-89.  We find that the 
conserved lysines (K115 and K356) within these SC motifs serve as the main sites for 
conjugation by members of the SUMO family.  By taking advantage of cellular contexts 
that harbor or are devoid of Sp-like factors, we demonstrate that the SC motifs do not 
alter the ability of ZBP-89 to displace Sp-like factors.  Rather, we find that by recruiting 
SUMO to ZBP-89, the SC motifs potently limit the intrinsic ability of ZBP-89 to 
synergistically activate transcription from reiterated binding sites (homotypic synergy) 
and to cooperate with nearby-bound heterologous factors (heterotypic synergy). 
MATERIALS AND METHODS 
Expression plasmids – An N-terminal, hexa-histidine-tagged, CMV-driven human ZBP-




TCCATGATGATGGTGGTGATGCTCCATG-GTGCCG-3', which contain a starting 
ATG codon within a consensus Kozak’s sequence followed by a hexa-histidine-tag were 
annealed and ligated into the BamHI and NheI sites of pcDNA3.1 (+) to yield pcDNA3.1 
(+)-His.  Human ZBP-89 cDNA was then PCR amplified using forward primer 5’-
GATGGATCCATGA-ACATTGACGACAAACTGGAAGG-3’ and reverse primer 5’-
CATCTCGAGTTAGCCAA-ACGTCTGGCCAGTTGTG-3’. The resulting fragment 
was digested with BamHI and XhoI and ligated into the same sites of pCDNA3.1(+)-His 
to yield pcDNA3.1 (+)-His-ZBP-89.  Single and double point mutations that replaced Lys 
115 and 356 with Arg were prepared using the QuikChange™ site-directed mutagenesis 
approach using pcDNA3.1 (+)-His-ZBP-89 as a template.  N-terminal HA-tagged ZBP-
89 expression plasmids were generated by ligating the 3092 bp BamHI/XbaI fragment 
from pcDNA3.1(+) His ZBP-89 into the same sites of pcDNA3.1(+) HA (Holmstrom et 
al., 2003). The expression vector for the non-cleavable fusion of HA-SUMO1 at the N 
terminus of ZBP-89 K115/356R was generated through excision of the HA-SUMO 
portion from pcDNA3 HA-SUMO1(-Gly) Gal4 (Holmstrom et al., 2003) as an 
NheI/BamHI fragment and ligation into the same sites of pcDNA3.1(+) His-ZBP-89 
K115/356R.  Fusions to HA-SUMO2, HA-SUMO2 K33E/K42E and SUMO3 were 
generated the same way using the corresponding pcDNA3 HA-SUMO (-Gly) Gal4 
vectors (Holmstrom et al., 2003; Chupreta et al., 2005).  The RSV-driven control (pS6R) 
and WT rat GR (p6R GR) expression vectors as well as the CMV-driven (pCDNA3) 
expression vectors for HA tagged SUMO1, SUMO2 and SUMO3 are described in 
(Iñiguez-Lluhí et al., 1997) and (Holmstrom et al., 2003).  pCMV β-gal is a CMV-driven 
β-galactosidase expression vector and was used to correct for transfection efficiency.  
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To generate ZBP-89 Drosophila expression plasmids, driven by the actin 5C 
promoter, two oligonucleotides 5’-GATCAGCTAGCGA-ATTCTCTAGAA-3’ and 5’-
AGCTTTCTAG-AGAATTCGCTAGCT-3’ containing NheI and XbaI restriction sites 
were annealed and ligated into the HindIII and BamHI sites of pA5C (kindly supplied by 
Dr. Thomas Kornberg, University of California, San Francisco) to yield pA5C*.  
NheI/XbaI fragments containing His-tagged WT or mutant ZBP-89 were excised from 
the corresponding pcDNA3.1 (+)His-ZBP-89 plasmids and ligated into the same sites of 
pA5C* to yield pA5C His-ZBP-89 and pA5C His-ZBP-89 K115/356R respectively.  
Non-cleavable fusions of HA SUMO isoforms at the N terminus of ZBP-89 K115/356R 
were generated by insertion of NheI/BamHI fragments exactly as described above for the 
mammalia expression of rat GR (pA5C GR) was generated by transferring the GR coding 
region (as a BamHI fragment) from p6RGR into the BamHI site of pA5C.  pPac Sp1 
(Courey and Tjian, 1988) and pActin β-gal (gift of Dr. Ken Cadigan, Univ. Michigan) are 
expression plasmids for Sp1 and β-galactosidase respectively and  are driven by the actin 
5C promoter.   
Reporter plasmids –The pΔODLO 02 reporter plasmid where a minimal Drosophila 
distal alcohol dehydrogenase promoter (-33 to +55) drives the luciferase gene is 
described in (Subramanian et al., 2003).  Luciferase reporter plasmids bearing one or 
more ZBP binding sites were generated as follows:  The oligonucleotides 5'-
GAGCCCCG-CCCCTCCCCCGCA-3' and 5'-GATCTGCGG-GGGAGGGGCGGG-3', 
containing a single ZBP-89 binding site from the ODC promoter (-114 to -100) (Law et 
al., 1998b) were annealed and ligated into the BamHI and BglII sites of pΔODLO 02 to 
yield pΔ(ODC)1-Luc.  Similar ligation of oligonucleotides 5’-
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GATCCTGTACAGGATG-TTCTA-3’ and 5’-GATCTAGAACATCCTGT-ACAG-3’ 
bearing a GRE from the tyrosine aminotransferase gene (Jantzen et al., 1987) yielded 
pΔ(TAT)1-Luc.  Reporter plasmids containing multiple ZBP-89 or GR binding sites were 
generated as follows: Ligation of independent BseRI/BglII and BamHI/BseRI fragments 
of pΔ(ODC)1-Luc yielded pΔ(ODC)2-Luc.  The same operation applied to pΔ(ODC)2-
Luc and pΔ(TAT)1-Luc yielded pΔ(ODC)4-Luc and pΔ(TAT)2-Luc.  Ligation of 
BseRI/BglII and BamHI/BseRI fragments of pΔ(ODC)1-Luc and pΔ(ODC)2-Luc 
respectively yielded pΔ(ODC)3-Luc.  The reporter plasmid bearing one ZBP-89 site 
upstream of a single glucocorticoid response element (pΔ(ODC)1(TAT)1-Luc) was 
generated by ligation of BseRI/BglII and BamHI/BseRI fragments from pΔ(ODC)1-Luc 
and pΔ(TAT)1-Luc  respectively.  The same strategy using pΔ(ODC)2-Luc and 
pΔ(TAT)2-Luc yielded pΔ(ODC)2(TAT)2-Luc.  The pODC-Luc reporter plasmid harbors 
the region from –400 to +79 of the human ornithine decarboxilase gene in the pGL2 
plasmid (Promega, Madison, WI).  
The Drosophila vector for Cell Culture and Transfections – Human embryonic kidney 
293T cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) 
supplemented with 5% fetal bovine serum (FBS).  Human AGS gastric carcinoma cells 
were cultured in DMEM media containing 10% FBS.  Drosophila melanogaster S2 cells 
were grown in Schneider’s medium (GIBCO) supplemented with 10% heat-inactivated 
FBS at 25 °C. Except for data in Fig 2B, all cell lines were transfected by using 
Lipofectamine™ and plus™ reagent (Invitrogen).  For in vivo SUMOylation 
experiments, 293T cells (2x106) were seeded onto 10 cm plates.  After 24 h, cells were 
co-transfected with 3 µg of His-tagged ZBP-89 expression plasmids and 7 µg of HA-
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SUMO expression plasmids or empty vector as indicated in Fig. 3.  Cells were harvested 
24 h after transfection in 0.75 ml of urea lysis buffer (8 M urea, 0.5 M NaCl, 45 mM 
Na2HPO4, 5 mM NaH2PO4, 10 mM imidazole, pH 8.0) and sonicated.  Lysates were 
incubated with 0.1 ml of 50% Ni2+-NTA-agarose (Qiagen) equilibrated in lysis buffer for 
1 h at room temperature with rocking.  The resin was then washed three times with 10 
bed volumes of wash buffer 1 (8 M urea, 0.4 M NaCl, 17.6 mM Na2HPO4, 32.4 mM 
NaH2PO4, 10 mM imidazole, pH 6.75) and two times with wash buffer 2 (buffer 1 with 
150 mM NaCl and no urea).  Proteins were eluted by boiling in 50 μl 2X Laemli sample 
buffer, resolved by 7.5% SDS-PAGE and processed for immunoblotting as described 
below. 
For in vivo SUMOylation in AGS cells, 2x106 cells were seeded in 10 cm plates 
and transiently transfected using the calcium phosphate method with the constructs 
indicated in the figure legend. 40 hours post-transfection, cells were lysed for 10 min on 
ice with 0.75 ml of high salt lysis buffer (20 mM Hepes, pH 7.5, 5 mM EDTA, 1 mM 
EGTA 1% NP40, 400 mM NaCl, 20 mM N-ethylmaleimide (NEM), and 1 tablet per 10 
ml of buffer of EDTA-free protease inhibitors (Roche).  After 5 minutes, NEM was 
quenched by addition of DTT to 40 µM final and a further 2 min. incubation.  Five 
percent of the sample was reserved for further analysis, and the remaining cell extracts 
were incubated with monoclonal HA-11 antibody (Covance, Berkeley, CA) and protein-
A agarose (Invitrogen) at 4 °C overnight. The immuno- precipitates were washed four 
times in low salt lysis buffer (high salt lysis buffer containing 200 mM NaCl), and eluted 
in 2X Laemli sample buffer. Samples were resolved by 7.5% SDS-PAGE and processed 
for immunoblotting as described below. 
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For functional assays, AGS cells (2x104) were seeded (0.5 ml) onto 24-well 
plates.  Cells were transfected 24 h later with the indicated amounts of ZBP-89 
expression plasmids.  To control for promoter dosage effects, cells treated with sub-
maximal amounts of ZBP-89 expression vector also received the required amount of 
empty expression vector to maintain equimolar doses of expression plasmid.  Cells also 
received 25 ng of the indicated luciferase reporter plasmid and 25 ng of pCMV β-gal.  
For Fig.5D, cells also received 20 ng of p6RGR expression plasmid.  In all cases, the 
total amount of DNA was supplemented to 0.3 μg/well with pBSKS(+).  For experiments 
including GR, media was supplemented 16 h post-transfection to 10 nM dexamethasone 
(Dex) or vehicle (0.1% ethanol).  Cells were lysed 36 h after transfection and luciferase 
and β-galactosidase activities were determined as described (Iñiguez-Lluhí et al., 1997).  
Functional assays in S2 cells were carried out by seeding in 24-well plates (8 x 104 
cells/well, 0.5 ml) followed 24 h later by transfection with the amounts of expression 
plasmids indicated in the figure legends.  All conditions contained equimolar amounts of 
each type of expression vector to control for promoter dosage effects.  Cells also received 
50 ng of the indicated luciferase reporter plasmid and 50 ng of pActin β-gal.  For the GR 
experiments, transfections included 100 ng of pA5C GR and cells were stimulated with 
100 nM Dex for the last 24 hr.  The total amount of DNA was supplemented to 0.3 
μg/well with pBSKS(+).  Cells were harvested 48 h post-transfection and processed as 
described above.   
Immunoblotting – For the in vivo SUMOylation experiments, immunoblots were probed 
with primary mouse anti tetra-His (Qiagen, USA), rabbit anti-ZBP-89 antiserum or HA-
11 (Covance, Berkeley, CA) monoclonal antibodies followed by goat anti mouse or 
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donkey anti-rabbit IgG peroxidase conjugated (Bio-Rad) secondary antibodies.  ZBP-89 
and GR expression levels were confirmed by western blotting.  Cells were transfected as 
described for the functional assays and lysed in 1X SDS PAGE sample buffer containing 
150 mM NaCl 36 h after transfection, resolved on 7.5% SDS-PAGE gels and processed 
for immunoblotting.  Mammalian transfection samples were probed with HA-11 
(Covance, Berkeley, CA) monoclonal antibody followed by goat anti mouse IgG 
peroxidase conjugate (Bio-Rad) as secondary.  For transfections in Drosophila cells, 
ZBP-89 and derivatives were detected with an anti ZBP-89 rabbit serum followed by 
secondary goat anti-rabbit IgG peroxidase conjugate (Bio-Rad).  GR was detected using 
BuGR2 (Covance, Berkeley, CA) primary and goat anti-mouse IgG peroxidase conjugate 
secondary antibodies.  Images were captured in a Kodak Image Station 440 CF using 
Super Signal West Femto substrates (Pierce).  All the experiments were performed at 
least thrice with similar results 
Protein-protein interaction and in vitro SUMO conjugation assays – ZBP-89 forms or 
luciferase were synthesized in vitro using the T7-TNT Quick™ Coupled Transcription-
Translation system (Promega) in the presence of [35S] methionine using pCDNA3.1(+) 
His-ZBP-89 or Luciferase plasmids as templates.  Binding reactions (50 μl) were 
performed at 4 °C and contained 1.2 nmol of GST or GST-UBC9 fusion protein 
(Subramanian et al., 2003) bound to 20 µl of glutathione-Sepharose 4B (Amersham 
Biosciences) in binding buffer (50 mM NaCl and 1 mg/ml bovine serum albumin) and 10 
µl of radiolabeled proteins.  After 1 h incubation with rocking, the resin was washed four 
times with 0.1% Nonidet P-40 in phosphate-buffered saline.  Samples were eluted by 
boiling in 40 µl of SDS-PAGE sample buffer, resolved on 7.5% SDS-PAGE gels and 
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radioactive proteins were visualized using a PhosphorImager screen (Amersham 
Biosciences).  
SUMOylation reactions were carried out in 20 µl of 50 mM Tris (pH 7.5), 5 mM 
MgCl2 and in presence (as indicated) of 1 µg of GST SAE2/SAE1, 5 µg of GST hUBC9, 
5 µg of His-SUMO-1GG (Subramanian et al., 2003) and 5 µl of in vitro translated [35S] 
labeled His-ZBP-89 WT or its SUMOylation deficient mutants or luciferase control as 
indicated.  Reactions were initiated by the addition of an ATP regeneration system (final 
concentrations: 10 units/ml creatine kinase, 25 mM phosphocreatine, 5 mM ATP) and 
pyrophosphatase (0.6 units/ml final).  Samples were incubated at 30° C for 90 min and 
reactions were terminated by addition of 20 µl disruption buffer (50 mM Tris-HCl, pH 
6.8, 1.67% SDS, 10% glycerol, 0.24 M β-mercaptoethanol, 0.015% bromophenol blue) 
and boiling for 5 min.  Samples were resolved by 7.5% SDS-PAGE and radioactive 
proteins were visualized as above. 
RESULTS 
ZBP-89 interacts with Ubc9 and is a target of SUMOylation at two conserved SC 
motifs – Bioinformatic analysis of ZBP-89 revealed the presence of two sequences 
resembling synergy control motifs located in the N-terminal half of the protein 
surrounding the zinc-finger DNA binding domain (Fig. A.2.1).  Analysis of the sequence 
conservation in the SC motif regions shows that the cardinal features of SC motifs, 
including flanking proline residues, are conserved across vertebrate species, including 
distant teleost fish.  In contrast, surrounding sequences and the third and non-essential 
position of the SC motif are more variable, suggesting the presence of a selective 
pressure for the conservation of the SC motifs and their associated functions.  SC motifs 
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serve as sites for SUMOylation through their direct interaction with Ubc9.  Notably, we 
recently isolated Ubc9 in a yeast two hybrid screen using ZBP-89 as bait (data not 
shown).  To confirm this interaction, we carried out in vitro interaction assays using 
immobilized GST-Ubc9 fusion protein as an affinity resin.  As can be seen in Fig. 
A.2.2A, in vitro transcribed and translated ZBP-89 is efficiently retained on this matrix 
but no binding is observed to an equimolar amount of GST.  In arginines (ZBP-89 mut) 
did not interfere with this interaction (Fig. A.2.2A, right).  
The identification of Ubc9 as an interaction partner of ZBP-89 coupled with the 
presence of well-conserved synergy control motifs within its sequence strongly suggested 
that this factor is likely to be subject to SUMO modification.  To examine this possibility 
directly, we transiently transfected human AGS gastric carcinoma cells with expression 
vectors for HA-tagged SUMO3 and ZBP-89 (Fig. A.2.2).  Immunoblotting of cell 
extracts with the anti-ZBP-89 antibody reveals the expression of both endogenous as well 
as exogenous ZBP-89 (middle panel).  Similarly, probing with an anti-HA antibody 
demonstrates the incorporation of SUMO3 into cellular proteins (lower panel).  Analysis 
of HA immunoprecipitates from cells expressing both ZBP-89 and HA SUMO3 revealed 
the presence of a ~160 kDa slower mobility form in addition to smaller amounts of 
unmodified ZBP-89 (Fig. A.2.2B top panel).  The upper band is consistent with SUMO 
modification whereas the unmodified material probably derives from dimerization of 
modified and non-modified forms of ZBP-89.  Notably, small amounts of a similar slow-
migrating species are also detected from cells expressing exclusively HA-SUMO3, 
suggesting that endogenous ZBP-89 is also modified.  To confirm and characterize the 
SUMOylation of ZBP-89, we expressed N-terminally His-tagged WT ZBP-89 and HA-
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tagged SUMO1, SUMO2, or SUMO3 in HEK 293T cells.  Cells were lysed under 
denaturing conditions (8M Urea) in an effort to preserve the SUMOylation status of 
cellular proteins and to disrupt non-covalent interactions.  The cleared lysates were 
subjected to Ni2+ chelate chromatography to isolate his-tagged ZBP-89, and samples were 
resolved by SDS-PAGE and analyzed by western blotting.  As can be seen in Fig. 
A.2.3A, co-expression of ZBP-89 with any of the three SUMO isoforms resulted in the 
appearance of a ~160 kDa HA immunoreactive band.  This species was not observed 
when either SUMO or ZBP-89 were expressed alone and is indicative of a SUMO-
modified form of ZBP-89.  As in the case of other transcription factors, (Johnson, 2004; 
Hay, 2005) the stoichiometry of modification appears to be relatively low since the 
SUMO-modified contrast, firefly luciferase, which lacks sequences resembling SC 
motifs, did not bind to either matrix.  Consistent with the known binding properties of 
Ubc9, replacement of the lysine residues within the SC motifs by form was difficult to 
detect with the ZBP-89 directed antibodies we examined.  Although we have not 
analyzed the linkage topology, the large apparent size of this form may be consistent with 
a single SUMO modification since branched SUMO-modified proteins often run 
anomalously in SDS-PAGE.  Moreover, ZBP-89 may be particularly prone to such 
anomalous behavior since the full-length protein migrates substantially slower than the 
predicted 89 kDa (Fig. A.2.3B).  Analysis of crude cell lysates revealed that SUMO 
conjugates as well as free SUMO accumulate to substantially higher levels in the case of 
SUMO2 and 3 when compared to SUMO1 (see supplemental Figure 1 and (Subramanian 
et al., 2003)).  Nevertheless, comparable levels of ZBP-89 SUMOylation were observed 
with all three SUMO isoforms.  Whether this reflects a relative preference for SUMO1 
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modification of ZBP-89 remains to be explored in more detail.  To examine the role of 
the putative SC motifs in ZBP-89 SUMOylation, samples were isolated from cells 
expressing ZBP-89 mutants bearing a Lys to Arg substitution in either the first (K115R), 
second (K356R) or both SC motifs (K115/356R).  As can be seen in Fig. A.2.3A, each 
substitution did not substantially reduce the ~160 kDa form whereas the double mutant 
essentially eliminated it.  Probing of the same samples with an anti-His-tag antibody (Fig. 
A.2.3B), indicated that neither the expression of SUMO isoforms, nor the presence of the 
mutations alter the expression or recovery of ZBP-89. Taken together, the results strongly 
support the idea that in vivo ZBP-89 is a target of SUMO modification, that all three 
SUMO isoforms can be conjugated to ZBP-89, and that the main sites of modification 




Figure A.2.1.  ZBP-89 harbors two conserved Synergy Control motifs Top: schematic 
representation of human ZBP-89 highlighting key structural features.  CR1-3: Conserved 
Regions 1 to 3.  The two Synergy Control (SC) motifs flanking the DNA binding domain 
are shown underlined.  Bottom: alignment of ZBP-89 sequences centered on the first and 
second SC motifs.  Numbering corresponds to the human sequence.  The core SC motifs 
as well as flanking proline residues are boxed.  Lysines (K115 and K356) targeted for 
SUMOylation are bold.  The consensus sequence for SC motifs and SUMOylation sites 







Figure A.2.2.  ZBP-89 interacts with Ubc-9 and is a target of SUMOylation.  A) In vitro 
interaction between ZBP-89 and Ubc9.  Purified GST or GST-Ubc9 fusion proteins 
bound to glutathione-sepharose beads were incubated with the indicated in vitro 
translated and [35S]-labeled proteins and processed as described in Materials and 
Methods.  ZBP-89 mut corresponds to the K115R/K356R double mutant.  Load 
corresponds to 10% of applied material.  B) In vivo SUMOylation of ZBP-89. AGS cells 
were transfected with expression plasmids pCDNA3.1(+)-His ZBP-89 WT (WT), 
pCDNA3 HA-SUMO3 or the corresponding empty vectors as indicated. Cells were lysed 
after 24 hrs and extracts immunoprecipitated with anti HA antibodies as described in 
Materials and Methods.  Extracts and immunoprecipitates were processed for 
immunoblotting with anti HA (bottom panel) or anti-ZBP-89 antibodies.  Open and 






Figure A.2.3.  In vivo modification of ZBP-89 by different SUMO isoforms requires 
intact SC motifs.  Human 293T cells were transfected as described in Materials and 
Methods with either control pCDNA3.1(+) vector (-),  pCDNA3.1(+)-His ZBP-89 WT 
(WT), or pCDNA3.1(+)-His ZBP-89 single (K115R and K356R) and double 
(K115R/K356R) mutants along with pCDNA3 HA-SUMO1, 2 or 3 as indicated.  Cells 
were lysed 24 h after transfection under denaturing conditions.  Proteins were purified 
using Ni2+-NTA resin as described in "Materials and Methods" and processed for 
immunoblotting with anti HA (panel A) and anti hexa-His (panel B) antibodies.  The 
positions of intact and SUMO-modified ZBP-89 are indicated by open and closed 






Figure A.2.4.  The SC motifs in ZBP-89 are SUMO-modified in vitro. A) In vitro 
translated [35S]-labeled ZBP-89 WT (left) or luciferase control protein (right) were used 
as substrates for in vitro SUMOylation reactions in the presence or absence of the 
indicated purified proteins: His-SUMO1, GST-Ubc9 and GST-SAE1/SAE2 as described 
in Materials and Methods.  Samples were resolved by SDS-PAGE and visualized using a 
PhosphorImager.  B) In vitro translated [35S]-labeled ZBP-89 WT (WT) and the indicated 
mutants were subjected to in vitro SUMOylation reactions in the presence of all required 
components.  In both panels, the positions of intact and SUMO-modified ZBP-89 are 




To further investigate the mechanism of ZBP-89 SUMO modification, we 
employed a reconstituted in vitro SUMOylation assay consisting of purified recombinant 
SUMO1 as well as E1 (SAE1/SAE2) and E2 (Ubc9) enzymes.  SUMOylation targets 
consisted of in vitro translated [35S]-labeled proteins.  As in the in vivo experiments, in 
vitro synthesized His-tagged ZBP-89 migrated with an apparent Mr of ~110 kDa (Fig. 
A.2.4A).  Incubation with all SUMOylation machinery components led to the generation 
of slower migrating bands of ~160 and 220 kDa consistent with mono- and di-
SUMOylated forms of ZBP-89.  Omission of the E1 or E2 enzymes or SUMO itself 
during the reaction prevented the appearance of the slowly migrating species (Fig. 
A.2.4A), indicating that they represent specific covalent modification of ZBP-89 by 
SUMO1.  In contrast, in vitro transcribed firefly luciferase, which lacks sequences related 
to SC motifs, did not serve as substrate (Fig. A.2.4A, right).  Similar results were 
obtained with SUMO2 (not shown).  In contrast to WT ZBP-89 and in agreement with 
the in vivo experiments, the higher molecular weight species are absent in the case of the 
K115R/K356R mutant, in which both potential SUMOylation sites are disrupted (Fig. 
A.2.4B).  Interestingly, the Lys to Arg substitution at position 115 produces a more 
significant reduction in SUMOylation than that observed with the substitution at position 
356, suggesting a preferential targeting of Lys 115 under our in vitro conditions.  This 
mild bias however, was not detected in the in vivo experiments.  Taken together the 
above results argue strongly that the lysine residues within the first and second SC motifs 
of ZBP-89 (Lys115 and Lys356) serve as the main sites for conjugation of all three 
SUMO isoforms both in vivo and in vitro. 
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The SC motifs in ZBP-89 exert a SUMO-dependent inhibitory effect only at compound 
response elements– Given our previous characterization of SC motifs in other factors, we 
anticipated that the functional effects of the SC motifs in ZBP-89 would be restricted to 
contexts where multiple instances of one or more SUMOylated factors are recruited to 
independent sites on DNA (Iñiguez-Lluhí and Pearce, 2000; Holmstrom et al., 2003).  To 
determine the functional role of the SC motifs in ZBP-89, we generated HA-tagged 
expression vectors for the K115/356R double mutant (ZBP-89 mut) as well as for a non-
cleavable fusion between SUMO1 and the ZBP-89 mutant lacking its own SUMOylation 
sites (SUMO1-ZBP-89 mut).  The former plasmid generates a ZBP-89 form with 
disabled SC motifs (due to the loss of SUMO modification), whereas the latter mimics a 
persistently SUMOylated form of ZBP-89.  The fusion strategy is particularly useful 
since it allows for selective recruitment of SUMO to a specific factor without interfering 
with the endogenous complement of SUMO modified proteins.  Moreover, in the cases 
where it has been examined in detail, the fusions accurately recapitulate the principal 
effects of SUMOylation (Holmstrom et al., 2003).  We first compared the activity of the 
SUMOylation mutant and SUMO-fused forms to WT ZBP-89 at reporter genes bearing 
either one or three copies of a GC site from the ornithine decarboxilase (ODC) gene (Law 
et al., 1998b).  Sp1 and ZBP-89 bind this element in a mutually exclusive manner and 
ZBP-89 antagonizes the effects of Sp1 through a displacement mechanism (Law et al., 
1998b).  In human AGS gastric carcinoma cells, these reporters display substantial basal 
activity compared to a control reporter lacking ODC sequences (Fig. A.2.5A and B).  
This activity is mainly attributable to endogenous Sp1 (Law et al., 1998b).  Transfection 
of increasing doses of expression plasmid encoding ZBP-89 led to a dose-dependent 
 145
 
inhibition of both promoters.  At the reporter containing a single ZBP-89 binding site 
(Fig. A.2.5A), where presumably only one protein can be present at a time, the 
SUMOylation mutant and the SUMO fusion displayed comparable activities to WT ZBP-
89, indicating that SUMOylation does not appear to influence the ability to bind the 
response element and displace endogenous Sp1-like factors.  The comparable activities 
are also consistent with the equivalent expression levels of the three forms (Fig. A.2.5 
inset).  At the reporter bearing three copies of the element however, (Fig. A.2.5B) we 
consistently observed that at intermediate doses, the SUMOylation deficient ZBP-89 was 
a weaker inhibitor whereas the SUMO1 fused ZBP-89 was a stronger inhibitor compared 
to WT ZBP-89.  Given that the intact proximal promoter of the ODC gene harbors 
multiple GC rich elements, we anticipated that ZBP-89 SUMOylation would also 
influence transcriptional inhibition at the native promoter.  As seen in Fig. A.2.5C, this 
appears to be the case since the inhibition pattern is similar to that observed at the simpler 
(ODC)3 reporter. In addition, we obtained similar results in the case of the proximal 
gastrin promoter (not shown).  Given that at both the natural and (ODC)3 reporters Sp1-
like factors and ZBP-89 can be recruited simultaneously through occupancy of 
independent sites, the data indicate that SUMOylation of ZBP-89 exerts a negative 
influence on the transcription complexes that assemble at compound response elements. 
If ZBP-89 SUMOylation acts to inhibit mixed or heterotypic complexes, this 
modification should also influence the activity of unrelated activators bound nearby.  To 
examine this point, we took advantage of the well-described synergistic cooperation 
between CACCC box binding factors such as Sp1 and the glucocorticoid receptor 
(Strähle et al., 1988; Müller et al., 1991).  As can be seen in Fig. A.2.5 D, the activity of a 
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target gene bearing a single ODC element upstream of a single glucocorticoid response 
element from the tyrosine aminotransferase gene [(ODC)1-(TAT)1] is substantially higher 
upon activation of the glucocorticoid receptor with dexamethasone, than in its absence 
(endogenous Sp-like factors alone).  The activity is also higher when compared to a 
reporter bearing only a single TAT element (GR activity alone, data not shown).  
Expression of ZBP-89 in this context resulted in a dose-dependent inhibition of activity.  
Notably, the SUMOylation deficient ZBP-89 was a weaker inhibitor as evidenced by a 
rightward shift in the dose-response.  This difference is due to loss of SUMOylation since 
fusion of SUMO1 to the ZBP-89 mutant restored its inhibitory potential.  A similar 
pattern, with slightly more pronounced differences was observed at a reporter bearing 
two copies of each response element (not shown).  Taken together, the above results 
indicate that SUMOylation of ZBP-89 modulates its ability to regulate transcription in 
mammalian cells, mainly by altering cooperation with other factors.  Thus, at compound 
response elements, complexes including SUMOylated ZBP-89 are less conducive to 
transcriptional activation. 
ZBP-89 antagonizes Sp1 through displacement and SUMOylation-dependent 
inhibition of synergy at compound response elements in Drosophila S2 cells – As 
mentioned above, the effects of ZBP-89 in mammalian cells likely depend on both its 
intrinsic transcriptional properties as well as on its ability to compete for response 
element occupancy with other factors.  To evaluate the role of SUMOylation in each of 
these contexts and to define more clearly the intrinsic properties of ZBP-89, we turned to 
Drosophila Schneider S2 cells.  This model has proven extremely valuable to study Sp-
like factors since, unlike most mammalian cells, they are functionally devoid of this class 
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of regulators (Courey and Tjian, 1988).  To determine whether it is possible to 
recapitulate the effects observed in mammalian cells, we examined the ability of ZBP-89 
to inhibit Sp1 driven activity at promoters bearing one or three copies of the ODC 
response element (Fig. A.2.6).  As expected, in the absence of Sp1, the activity of these 
reporters was negligible (indistinguishable from the background signal from 
untransfected cells).  Expression of Sp1 led to a robust activation of these reporters with 
the activity at the (ODC)3 reporter being nearly four-fold higher than that of the reporter 
bearing a single site.  As in mammalian cells, expression of ZBP-89 led to a dose-
dependent inhibition of activity.  At the reporter with a single ODC response element, we 
did not detect significant differences between WT ZBP-89 and the SC motif mutant or 
the SC motif mutant SUMO-1 fusion (Fig A.2.6A).  These data parallel the observations 
in mammalian cells (Fig. A.2.5A) and further support that SUMOylation of ZBP-89 does 
not alter its ability to compete with Sp1 for occupancy of the response element.  In the 
case of the reporter bearing three response elements (Fig A.2.6B), disruption of the SC 
motifs in ZBP-89 reduced, whereas the SUMO1 fusion enhanced the ability of ZBP-89 to 
inhibit transcription.  The data reiterate the observations in mammalian cells (Fig. 
A.2.5B) and indicate that SUMO modification of ZBP-89 reduces the transcriptional 
output of complexes assembled at compound response elements.  Clearly, the ability to 
recapitulate the ZBP-89 mediated transcriptional effects obtained in mammalian cells 
validates Schneider S2 cells as an adequate model to probe the effects of SUMO 




Figure A.2.5.  In mammalian cells, SUMOylation of the SC motifs in ZBP-89 influence 
its inhibitory activity in a promoter-dependent manner. AGS cells were co-transfected as 
described in Materials and Methods with the indicated amounts of expression vectors for 
HA-WT ZBP-89 (open circles), the K115R/K356R double mutant that disrupts both SC 
motifs (open diamonds) or for an N-terminal fusion of SUMO1 to the double mutant 
ZBP-89 (shaded diamonds).  Cells were co-transfected with luciferase reporter plasmids 
driven by one A) or three B) ZBP-89 binding sites from the ODC gene or by the proximal 
ODC promoter C).  AGS cells were co-transfected with the indicated amounts of ZBP-89 
expression plasmids and a constant amount (20 ng) of GR expression plasmid together 
with a reporter plasmid containing one copy each of both ZBP-89 (ODC) and GR (TAT) 
binding sites.  Cells were treated 24 h after transfection with 10 nM dexamethasone 
(+Dex) or vehicle (-Dex) and processed as described in “Materials and Methods”.  The 
data represent the average ± SEM of at least three independent experiments performed in 
triplicate and are expressed as a percentage of the activity in the absence of ZBP-89 
(panels A, B and C) or GR + Dex activity alone (panel D).  The corresponding reference 
values for each reporter are: pΔODC1-Luc (0.300 ± 0.009), pΔODC3-Luc (0.618 ± 
0.041), pODC-Luc (0.996 ± 0.042) pΔODC1TAT1-Luc (0.996 ± 0.042).  The inset shows 




Figure A.2.6.  SUMO modification enhances the ability of ZBP-89 to antagonize Sp1 in 
Drosophila cells only at promoters harboring multiple binding sites.  Drosophila S2 cells 
were co-transfected with the indicated amounts of expression vectors for WT ZBP-89 
(open circles), the K115R/K356R double mutant that disrupts both SC motifs (open 
diamonds), or for an N-terminal fusion of SUMO1 to the double mutant ZBP-89 (shaded 
diamonds).  Cells received a constant amount (10 ng) of Sp1 expression plasmid and 
luciferase reporter plasmids containing one (pΔODC1-Luc, A) or three (pΔODC3-Luc, B) 
ZBP-89 binding sites from the ODC gene.  Data represent the average ± SEM of at least 
three independent experiments performed in triplicate and are expressed as a percentage 
of the activity in the presence of Sp1 alone, which amounted to 2.44 ± 0.18 and 9.39 ± 
0.71 for pΔODC1-Luc and pΔODC3-Luc respectively. 
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In the absence of Sp1, ZBP-89 functions as an activator whose synergy potential is 
restricted by SC motifs – The functional antagonism evident in Figs A.2.5 and A.2.6 
indicates that ZBP-89 can compete with Sp1 for common binding sites.  The substantial 
residual activity at the highest doses of ZBP-89 expression plasmid however, suggested 
that ZBP-89 may possess intrinsic transcriptional activation properties that could be 
modulated by SUMO modification.  To probe this question directly, we examined the 
activity of ZBP-89 in the absence of competing factors (S2 cells) at reporter genes 
harboring from zero to four copies of the ODC response element.  As can be seen in Fig. 
A.2.7, expression of WT ZBP-89 caused a ~3-fold activation of the reporter bearing a 
single ODC response element.  Notably, the presence of additional response elements did 
not lead to significant enhancements in activity (Fig. A.2.A.2.7, closed bars).  This 
indicates that ZBP-89 can function as a modest activator, but its ability to engage in 
homotypic synergistic interactions is severely limited.  Consistent with our model of 
synergy control, disruption of the SC motifs in ZBP-89 did not affect its activity at a 
single site, but led to a substantial enhancement at reporters bearing multiple sites (Fig. 
A.2.7, hatched bars).  Notably, the expansion of the number of response elements results 
in synergistic effects since the activity is higher than predicted from purely additive 
effects (dashed lines).  Taken together, these results indicate that ZBP-89 is capable of 
activating transcription, and that the SC motifs in ZBP-89 limit its homotypic synergy 
potential at compound response elements.  Given the much greater relative activity of 
Sp1 (>10 fold compared to ZBP-89), it is therefore clear how in cellular contexts where 
Sp1 is present, replacement by ZBP-89 leads to a lower overall activity. 
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SUMO isoforms mediate the functional effects of the SC motifs through a distinct 
functional surface – Disruption of the SC motifs in ZBP-89 leads to both loss of 
SUMOylation and to a loss of synergy control.  This suggests that SC motifs exert their 
effects by serving as SUMO acceptor sites.  Moreover, the ability of the SUMO1 fusion 
to recapitulate the functional effects of SC motifs indicates that recruitment of SUMO 
isoforms to ZBP-89 leads to the observed functional effects.  To probe the ability of 
individual SUMO isoforms to regulate ZBP-89 function, we generated N-terminal 
fusions of all three SUMO isoforms to the SUMOylation-deficient SC motif mutant of 
ZBP-89 and examined their promoter-dependent activities in S2 cells.  At a promoter 
harboring a single ZBP-89 binding site (Fig. A.2.8A), both the WT (solid bar) and SC 
motif mutant (hatched bar) forms of ZBP-89 displayed identical activities (~3 fold over 
basal).  In contrast, at the promoter bearing three response elements, disruption of the SC 
motifs in ZBP-89 led to substantially greater (~2.6 fold) activation compared to WT 
ZBP-89 (Fig. A.2.8B). Fusion of either SUMO1, 2 or 3 to the SC mutant ZBP-89, which 
mimics the SUMOylated form of ZBP-89, led to a dramatic inhibition of activity at the 
promoter bearing three response elements (Fig. A.2.8B shadowed hatched bars).  Such 
severe inhibitory effects of SUMO isoforms suggest that even at the low stoichiometry of 
modification observed in vivo, SUMOylation could have profound consequences on 
activity.  Interestingly, the SUMO fusions also led to a striking inhibition of activity at 
the promoter bearing a single response element (Fig. A.2.8A, shaded hatched bars).  The 
fact that the WT and SC motif mutant have comparable activities at this promoter may 
indicate that the stoichiometry of modification may not be sufficiently high to cause an 
effect in this context.  It is also possible that the N-terminal fusions do not fully 
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reproduce all of the properties of ZBP-89 when SUMOylated at its endogenous SC 
motifs.  The results from both promoters however, clearly indicate that ZBP-89 activity is 
exceedingly sensitive to the inhibitory effects of all three SUMO isoforms.  Through a 
detailed analysis, we have recently identified a highly conserved surface in SUMO that is 
responsible for its inhibitory properties on multiple transcription factors (Chupreta et al., 
2005).  Disruption of this SUMO effector surface by substitution of two critical basic 
residues (Lys 33, Lys 42 in SUMO2) by glutamic acid dramatically affects the ability of 
SUMO to inhibit transcription (Chupreta et al., 2005).  Importantly, and in contrast to 
WT SUMO2, fusion of the K33/42E SUMO2 mutant to ZBP-89 failed to inhibit activity 
at the (ODC)1 promoter and was substantially less inhibitory than WT SUMO2 at the 
(ODC)3 promoter (Fig. A.2.8 A and B).  Since all SUMO fusions are expressed at 
comparable levels, these results indicate that the inhibitory properties of SUMO on ZBP-
89 depend on its critical effector surface and are not simply due to steric hindrance 




Figure A.2.7.  In the absence of competing factors, homotypic synergistic activation by 
ZBP-89 is strongly inhibited by SC motifs. Drosophila S2 cells were co-transfected with 
100 ng expression vectors for ZBP-89 WT (solid bars), ZBP-89 SC motif double mutant 
(K115R/K356R, hatched bars) or equimolar amounts of control vector (pA5C, open bars) 
together with luciferase reporters harboring the indicated numbers of ZBP-89 response 
elements (RE).  Data represent the average ± SEM of at least three independent 
experiments performed in triplicate and are expressed as a fold induction over the activity 
obtained for the vector alone at the pΔ(ODC)0-Luc reporter (0.29 ± 0.02).  The dashed 
Reference lines indicate the predicted activity assuming simple additive effects.  The 





Figure A.2.8.  SUMO isoforms inhibit ZBP-89 activity through a critical effector surface. 
Drosophila S2 cells were co-transfected with 100 ng of control vector (pA5C, open bars) 
or expression vectors for ZBP-89 WT (solid bars), ZBP-89 SC motif double mutant 
(K115R/K356R, hatched bars) or ZBP-89 SC motif mutant fused to the indicated SUMO 
isoforms (shadowed hatched bars).  The SUMO2 mutant harbors the K33E and K42E 
mutations.  Reporter plasmids were pΔ(ODC)1-Luc (panel A) and pΔ(ODC)3-Luc (panel 
B).  Data represent the average ± SEM of at least three independent experiments 
performed in triplicate and are expressed as a fold induction over the activity obtained for 
the vector alone, which amounted to 1.03 ± 0.06 and 1.47 ± 0.08 for pΔ(ODC)1-Luc and 
pΔ(ODC)3-Luc respectively. The expression of the individual ZBP-89 variants as 





Figure A.2.9.  SUMOylation of ZBP-89 potently inhibits its ability to synergize with GR.  
Drosophila S2 cells were co-transfected with 100 ng of control vector (pA5C, open bars) 
or expression vectors for ZBP-89 WT (solid bars), ZBP-89 SC motif double mutant 
(K115R/K356R, hatched bars), or ZBP-89 SC motif mutant fused to the indicated SUMO 
isoforms (shadowed hatched bars). Cells also received 200ng expression vector for WT 
GR as indicated and the pΔ(ODC)2(TAT)2-Luc reporter.  The SUMO2 mutant harbors the 
K33E and K42E mutations.  Cells were treated with 100 nM dexamethasone 24 h after 
transfection, and were processed as described in Materials and Methods. Data represent 
the average ± SEM of at least three independent experiments performed in triplicate and 
are expressed relative to the activity obtained for GR alone (10.03 ± 2.01). The 
expression of the individual ZBP-89 variants and GR as determined by immunoblotting is 





SUMOylation of the SC motifs in ZBP-89 limits its ability to engage in heterotypic 
synergy with other activators – The above analysis indicates that ZBP-89 can function as 
an activator, and that modification by SUMO is an effective mechanism to inhibit its 
ability to self-synergize (homotypic synergy).  To examine both the ability of ZBP-89 to 
cooperate with other activators and the role of SUMOylation in such heterotypic synergy, 
we examined in S2 cells the functional interaction between WT GR and ZBP-89 at a 
promoter bearing two ZBP-89 binding sites upstream from two GREs (Fig. A.2.9).  In the 
absence of GR, the WT and mutant forms of ZBP-89 displayed a modest pattern of 
activity similar to that observed at the (ODC)2-Luc reporter.  Exclusive expression of GR, 
however, resulted in substantial ligand-dependent activation (~7 fold higher than WT 
ZBP-89).  Notably, co-expression with WT ZBP-89 led to a three-fold enhancement of 
activity compared to GR alone.  Thus, although ZBP-89 is a modest activator, it is able to 
synergize very effectively with GR.  Furthermore, disruption of the SC motifs in ZBP-89 
led to an even more substantial (~6.5 fold) enhancement of GR activity.  This indicates 
that, like in the case of homotypic interactions, the SC motifs strongly inhibit the 
heterotypic synergy potential of ZBP-89.  Remarkably, although fusion of any of the 
three SUMO isoforms to the SC motif deficient ZBP-89 does not affect expression, this 
maneuver essentially eliminates the amplifying effect on GR activity since the resulting 
activity is comparable to that of GR alone.  Furthermore, the inhibitory effect of SUMO 
requires an intact effector surface since fusion of the K33E/K42E SUMO2 mutant is 
much less effective (Fig. A.2.9, S2 mut).  Taken together, these results indicate that, by 
serving as sites of post-translational modification for SUMO, the SC motifs in ZBP-89 
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play an important role in controlling the transcriptional activity of this ubiquitous 
regulator.  
DISCUSSION 
The Synergy Control Motifs in ZBP-89 are sites for SUMO modification – Our finding 
that ZBP-89 interacts with Ubc9 and that the two SC motifs in ZBP-89 correspond to the 
main sites of SUMO modification extends the impact of the synergy control mechanism 
to this family of transcription factors.  The very recent demonstration of SUMO 
modification of other distantly related Krüppel type transcription factors (Karène et al., 
2005; Wei et al., 2006; Lee et al., 2007), as well as Sp1 (Spengler and Brattain, 2006), 
indicates that it is a widespread mechanism to regulate this broad class of regulators.  
Although all three SUMO isoforms can be conjugated to ZBP-89, the fact that SUMO2 
and 3 accumulate to substantially higher levels than SUMO1 argues for a preference for 
SUMO1 modification in vivo.  Although the intranuclear localization of ZBP-89 has not 
been defined, the distinct subnuclear targeting of isoform-specific SUMO proteases 
suggests that ZBP-89 may accumulate in regions enriched in SUMO2/3 specific 
proteases such as the nucleoli (Nishida et al., 2000; Gong and Yeh, 2006). Initial analysis 
of GFP fusions indicates that both WT and SC mutant ZBP-89 localize exclusively to the 
nucleus (not shown).  Likewise, the fact that the apparent preference for SUMOylation of 
K115 over K356 in vitro is not observed in vivo may be due to the actions of cellular 
activities such as E3 ligases that are absent in the in vitro assay.  Although lysine residues 
can be targets for multiple modifications, we do not observe alterations in the steady-state 
levels of ZBP-89 upon disruption of the SC motifs, suggesting that they are unlikely to 
contribute to ubiquitination-dependent degradation.  Furthermore, the ability of SUMO 
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fusions to reverse the effects of SC motif disruption argues strongly that SUMOylation is 
responsible for the function of the SC motifs. 
ZBP-89 as an activator and synergy partner regulated by SUMOylation – Although in 
most cases ZBP-89 appears to inhibit transcription of target genes, functional data 
suggests that it can exert a positive effect on transcription in certain contexts (Bai and 
Merchant, 2000; Yamada et al., 2001; Bai and Merchant, 2003) (Bai and Merchant, 2000; 
Yamada et al., 2001; Bai and Merchant, 2003). Whether this is due to a displacement 
mechanism or an intrinsic activation function remains unresolved.  We have obtained 
evidence that ZBP-89 can function as a direct albeit weak activator by taking advantage 
of S2 cells, which provide a cellular context devoid of competing factors.  This analysis 
is consistent with data derived from Gal4 DBD fusions to recruit ZBP-89 domains since 
Gal4 fusions to C-terminal fragments of ZBP-89 activate transcription from reiterated 
Gal4 sites (Hasegawa et al., 1997). In contrast to most activators, increasing the number 
of response elements did not lead to enhanced transcription. This lack of synergy was 
relieved by disruption of the SC motifs indicating that SUMOylation exerts a strong 
inhibitory effect on ZBP-89’s ability to engage in homotypic synergy.  Such behavior can 
be viewed as an extreme example of the synergy control mechanism observed in other 
activators such as GR, ETS-1 (Iñiguez-Lluhí and Pearce, 2000) and C/EBPα 
(Subramanian et al., 2003) and is akin to the properties of Sp3 (Ross et al., 2002; 
Sapetschnig et al., 2002).  Notably, although on its own ZBP-89 appears to be a weak 
activator, its remarkable ability to cooperate with other factors such as GR indicates that 
it has the capacity to exert quite substantial effects on activation when embedded in a 
complex promoter.  SUMOylation may therefore modulate the proposed cooperation 
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between ZBP-89 and JKTBP1 in the activation of the cytochrome c oxidase Vb gene 
(Boopathi et al., 2004).  In this view, ZBP-89 may serve a similar function to the 
“accessory factors” that are required for full glucocorticoid induction of metabolic genes 
such as PEPCK (Wang et al., 2004; Cassuto et al., 2005).  Consistent with a role in the 
regulation of synergistic transcription, the ability of ZBP-89 to cooperate with GR is 
inhibited by SUMO modification.  These data extend the role of SUMO modification to 
include heterotypic cooperation between different factors and suggests that SUMOylation 
is likely to be an important mechanism to regulate the concerted output of the 
transcription factor complexes that assemble at natural enhancers.  In contexts where 
ZBP-89 competes with other factors for a common site, the final functional effect of 
ZBP-89 will therefore depend not only on the relative intrinsic activities of the competing 
factors but also on their SUMOylation-regulated ability to cooperate with additional 
factors bound nearby. 
Inhibitory effect of ZBP-89 SUMOylation depends on recruitment to multiple binding 
sites and a critical surface in SUMO  In most cases, ZBP-89 functions as an inhibitor of 
transcription and displacement of stronger activators from GC rich sites is likely to be an 
important and widespread mechanism.  Notably, SUMOylation does not alter the ability 
to compete with Sp1 at a single site.  In contrast, at promoters bearing multiple sites 
where ZBP-89 can engage in heterotypic interactions with Sp1, ZBP-89 SUMO 
modification limits transcriptional activation. This is consistent with the role of 
SUMOylation as a mechanism to regulate higher-order interactions among transcription 
factors.  It is important to note that many sequence-specific factors are targets of 
SUMOylation and therefore at complex promoters there is substantial redundancy in 
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SUMO mediated inhibition. Consistent with this notion, our analysis of the effects of SC 
motifs in the glucocorticoid receptor indicate that the most dramatic effects of loss of 
SUMOylation are observed when all potential SUMOylation sites in a complex are 
disrupted (Iñiguez-Lluhí and Pearce, 2000; Holmstrom et al., 2003).  The recent 
demonstration that Sp1 is also subject to SUMO modification (Spengler and Brattain, 
2006) suggests that the relatively modest effect of disrupting the SUMOylation sites in 
ZBP-89 that we observe in mammalian cells may be due to a reduction, but not 
elimination of all potential SUMOylation sites at the promoter.  In addition, the analysis 
of Gal4 DBD fusions suggests that ZBP-89 harbors an intrinsic repressor function in the 
N-terminal region (Hasegawa et al., 1997; Passantino et al., 1998).  The implicated 
domain spans the two SC motifs and in the case of the vimentin gene, a direct repression 
mechanism involving HDAC recruitment has been invoked (Zhang et al., 2003; Wu et 
al., 2007).  Whether the SC motifs are sufficient to account for this activity or additional 
direct repressive functions are present in this N-terminal domain remains to be 
determined.  In the case of KLF-8 however, Wei et al. argue that SUMOylation 
attenuates the ability of KLF-8 to repress transcription at the KLF-4 promoter (Wei et al., 
2006).  Given the overlap in sequence specificity with other GC box binding proteins 
however it is difficult to determine whether this is due to a direct influence on an intrinsic 
repressive function or to factor displacement and altered cooperation effects.  Our data 
however, clearly indicate that the SUMOylation-dependent effects of SC motifs are 
restricted to promoter contexts where functional interactions involving multiple response 
elements take place.  Based on our mechanistic analysis, we have proposed that SUMO-
dependent recruitment of inhibitory cofactors may require a multivalent SUMO-target 
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interaction.  Conversely, the cofactors or machinery that mediates the inhibitory effects of 
SUMO may be able to antagonize only the activity emanating from stable complexes 
such as those that assemble at reiterated sites.  In this view, SUMO may inhibit from a 
single site as long as the stoichiometry is high and the DNA-activator binding is stable.  
The reduced activity of the ZBP-89 SUMO fusion at a single site may be an example of 
this scenario.  As in essentially all other examples of SUMOylation effects on 
transcription factors, this modification can exert a substantial effect even when the 
steady-state stochiometry of modification that can be detected is low.  Although the exact 
mechanism is unclear, it is possible that SUMOylation facilitates the establishment of an 
altered functional state (by facilitating or disrupting protein interactions for example).  
Once established, such a state may not require persistent SUMOylation for its 
maintenance.  Through an extensive, structurally based mutagenesis analysis, we 
(Chupreta et al., 2005) and others (Rosendorff et al., 2006) have identified a key 
conserved surface in SUMO responsible for its inhibitory effects on transcription.  X-ray 
(Reverter and Lima, 2005) and NMR structural analysis (Song et al., 2004) indicates that 
this effector region in SUMO interacts with Val/Leu-rich SUMO binding motifs in 
context-specific target proteins.  In this regard, certain Histone Deacetylases (Yang and 
Sharrocks, 2004) and DAXX (Lin et al., 2006), which harbor such motifs have been 
implicated in SUMO dependent inhibition of transcription. It is likely however, that 
additional processes are at play since we have been unable to demonstrate a role for these 
proteins in SC motif function.  It is clear however, that the effects of SUMO on ZBP-89 
do rely on this conserved functional surface of SUMO.  
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 The substantial impact of SUMOylation on the activity of ZBP-89 argues that it is 
likely to contribute to its regulation in vivo.  Given the important role of ZBP-89 for germ 
line and hematopoietic lineages, it is possible that developmental changes in ZBP-89 
SUMOylation could contribute to the temporally regulated and cell-type restricted 
activity of this otherwise mostly ubiquitous factor.  The recent demonstration that 
variations in the levels and activity of SUMOylation machinery components can 
accompany cellular differentiation programs (Jones et al., 2006) lends support to this 
view.  Identifying the proteins and signals that regulate ZBP-89 SUMOylation and 
interaction with other modifications will thus be informative.  Over-expression of ZBP-
89 leads to cell-cycle arrest and apoptosis both in cell culture (Bai and Merchant, 2001) 
and in intestinal tissues upon targeted transgenic expression (Law et al., 2006a).  A direct 
interaction between the Zn-finger region of ZBP-89 and p53 likely contributes to this 
effect (Bai and Merchant, 2001) (Bai and Merchant, 2001).  Interestingly, disruption of 
the SC motifs did not affect the ability of ZBP-89 to induce cell-cycle arrest (not shown). 
This suggests that SUMOylation may not interfere with p53 interactions or that arrest 
may depend on ZBP-89 transcriptional effects that involve displacement mechanisms 
insensitive to SUMOylation.  The influence of SUMOylation on transcription factor 
driven cell cycle effects appears to depend on the nature of the factor since SUMOylation 
of KLF-8 appears to inhibit the ability of this factor to promote entry into G1 (Wei et al., 
2006).  We have recently shown that a splice variant of ZBP-89 generated by alternative 
promoter usage yields an N-terminally truncated isoform.  Since the first SC motif is 
absent in this form, alterations in SUMOylation may contribute to the shortened lifespan 
and increased sensitivity to dextran-sulfate-sodium-induced colitis displayed by mice 
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exclusively expressing this N-terminally deleted form (Law et al., 2006b).  Taken 
together, our analysis indicates that by modulating the ability of ZBP-89 to engage in 
higher order functional interactions, SUMOylation offers a context-dependent post-
translational mechanism to regulate the activity of this multifunctional transcription 
factor.  
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